



## **Morbidity and Mortality Weekly Report**

www.cdc.gov/mmwr

Weekly

April 4, 2008 / Vol. 57 / No. 13

## Transplantation-Transmitted Tuberculosis — Oklahoma and Texas, 2007

Approximately 28,000 organ transplants were performed in the United States in 2007 (1). When infections are transmitted from donors, the implications can be serious for multiple recipients (2-4). Tuberculosis (TB), a known infectious disease complication associated with organ transplantation, occurs in an estimated 0.35%-6.5% of organ recipients in the United States and Europe posttransplantation (2). In 2007, the Oklahoma State Department of Health identified Mycobacterium tuberculosis in an organ donor 3 weeks after the donor's death. This report summarizes results of the subsequent investigation, which determined that disseminated TB occurred in two of three transplant recipients from this donor, and one recipient died. Genotypes of the donor and recipient TB isolates were identical, consistent with transmission of TB by organ transplantation. To reduce the risk for TB transmission associated with organ transplantation, organ recovery personnel should consider risk factors for TB when assessing all potential donors. In addition, clinicians should recognize that transplant recipients with TB might have unusual signs or symptoms. When transmission is suspected, investigation of potential donor-transmitted TB requires rapid communication among physicians, transplant centers, organ procurement organizations (OPOs), and public health authorities.

## **Case Report**

**Organ Donor.** In April 2007, a U.S.-born man aged 46 years with a history of seizure disorder, alcoholism, homelessness, and incarceration was admitted to an Oklahoma hospital for presumed alcohol withdrawal seizures and aspiration pneumonitis. He had a prolonged hospitalization characterized by altered mental status, fever, persistent pneumonia, hydrocephalus, multifocal cerebral infarction, and progressive neurologic disability attributed

to cerebral vasculitis. The patient continued to decline neurologically and met clinical criteria for brain death in early June 2007. Organs were recovered for transplantation, and the liver and kidneys were transplanted into three recipients, all Texas residents, at facilities in Oklahoma and Texas. Three weeks after the organ donor's death, a culture from cerebrospinal fluid obtained as part of his clinical evaluation for fever and altered mental status grew *M. tuberculosis*. Subsequently, *M. tuberculosis* also was cultured from stored donor spleen tissue.

The donor had been treated for presumed aspiration pneumonia with left lower lobe infiltrate and pleural effusion in December 2006, 6 months before his death. In March 2007, 1 month before his final hospitalization, the donor was again hospitalized for community-acquired pneumonia, shown on chest radiograph as involving the left upper and left lower lobe. He had no recognized history of TB or foreign travel and had not been identified as a contact of any person with TB. Two tuberculin skin tests (TSTs) performed during the 6 months before his death (one required by a homeless shelter, the other performed by the jail) were negative. No specimen was obtained for acid-fast bacilli (AFB) examination or mycobacterial culture.

## **INSIDE**

- 336 Nonfatal Maltreatment of Infants United States, October 2005–September 2006
- 340 Surveillance for Community-Associated Clostridium difficile Connecticut, 2006
- 343 Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24–59 Months Who Are Not Completely Vaccinated
- 344 Notices to Readers
- 346 QuickStats

The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Article title]. MMWR 2008;57:[inclusive page numbers].

## **Centers for Disease Control and Prevention**

Julie L. Gerberding, MD, MPH *Director* 

> Tanja Popovic, MD, PhD Chief Science Officer

James W. Stephens, PhD Associate Director for Science

Steven L. Solomon, MD

Director, Coordinating Center for Health Information and Service

Jay M. Bernhardt, PhD, MPH

Director, National Center for Health Marketing

Katherine L. Daniel, PhD

 $Deputy\ Director,\ National\ Center\ for\ Health\ Marketing$ 

#### **Editorial and Production Staff**

Frederic E. Shaw, MD, JD *Editor*, MMWR *Series* 

Teresa F. Rutledge

(Acting) Managing Editor, MMWR Series

Douglas W. Weatherwax Lead Technical Writer-Editor

Donald G. Meadows, MA

Jude C. Rutledge Writers-Editors

Peter M. Jenkins

(Acting) Lead Visual Information Specialist

Lynda G. Cupell

Malbea A. LaPete

Visual Information Specialists

Quang M. Doan, MBA

Erica R. Shaver

Information Technology Specialists

## **Editorial Board**

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

Recipient A. A woman aged 50 years received one of the donor's kidneys. In late July 2007, 6 weeks after the kidney transplant, she developed fever, followed by pancytopenia and a sepsis-like syndrome. At notification in late July the donor's positive culture for *M. tuberculosis*, a bone marrow aspirate was smear positive for AFB. Despite subsequent treatment with anti-TB therapy, the recipient died 9 weeks posttransplantation. The primary causes of death listed after autopsy were disseminated TB, leukopenia, and end-stage renal disease. *M. tuberculosis* was cultured from the deceased recipient's blood, liver, spleen, and lungs. The polymerase chain reaction (PCR)-based genotype and restriction fragment length polymorphism (RFLP) pattern of the recipient's *M. tuberculosis* isolate matched those of the donor.

**Recipient B.** A woman aged 23 years received the donor's other kidney, and had fever and severe headache in late July, 7 weeks after transplantation and concurrent with notification of the donor's positive M. tuberculosis culture. She was started on anti-TB medications. Her cerebrospinal fluid was negative on AFB smear and culture. Pancytopenia developed; although the patient's bone marrow aspirate revealed granulomas, the smear was negative for AFB. M. tuberculosis subsequently grew from the recipient's blood and urine specimens; these isolates had a PCR-based genotype and RFLP pattern matching that of the donor. The recipient experienced renal allograft dysfunction in August 2007, approximately 10 weeks after transplantation. Biopsy of the allograft revealed interstitial nephritis with negative AFB smear and culture; anti-TB medications were adjusted, and a course of low-dose steroids was added. As of this report, the patient was doing well, had stable renal allograft function, and was tolerating anti-TB medications.

**Recipient C.** The liver recipient, a man aged 59 years, was started on anti-TB treatment 2 months posttransplantation and had no symptoms of TB. Granulomas suggestive of mycobacterial infection were detected from a routine posttransplantation liver biopsy in January 2008, 7 months posttransplantation, while the recipient continued anti-TB treatment. AFB smear was negative, and culture identified *Mycobacterium avium* complex, a nontuberculous species of mycobacteria. No *M. tuberculosis* was cultured.

Contact investigations were conducted to evaluate at-risk hospital workers, close personal contacts, and family members related to the donor and recipients. No transmission of TB infection has been documented through contact investigation.

**Reported by:** V Kohli, MD, Integris Baptist Medical Center, Oklahoma City; L Smithee, MS, Oklahoma State Dept of Health. K Ishihara, MD, Univ of Texas Medical Branch at Galveston; L Ostrosky-Zeichner, MD,

C Van Buren, MD, J Lappin, MD, Univ of Texas Health Science Center at Houston. T Harrington, MD, Div of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; M Kuehnert, MD, Div of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases; E Piercefield, MD, DVM, EIS Officer, CDC.

Editorial Note: The majority of TB cases among organ transplant recipients are caused by activation of latent tuberculosis infection (LTBI) in the recipient once immunosuppressive medications are started to prevent organ rejection; a minority are attributed to donor transmission. In one international study, 4% of TB infections in recipients were considered donor derived (2). In this case report, genotyping supported the conclusion that transmission of TB occurred by organ transplantation to two recipients from a common donor. Although organ procurement protocols were followed, pretransplantation screening did not identify TB in the donor.

In the United States, all potential organ donors are screened to prevent transmission of infectious diseases, including TB, by organ transplantation. Minimum standards for donor eligibility are defined by United Network for Organ Sharing (UNOS), a nonprofit, private organization under government contract with the Health Resources and Services Administration to coordinate U.S. transplant activities (5). To evaluate eligibility, 1) the donor's medical record is reviewed for specific conditions (such as known active TB), 2) a medical and social history is conducted with next of kin (or other suitable person familiar with the donor), and 3) selected laboratory testing (such as testing for human immunodeficiency virus, hepatitis, and good organ function) and a chest radiograph are performed. No standard assessment is conducted to determine specifically whether the potential donor is at risk for having previously undiagnosed TB or LTBI. Although the screening process might uncover symptoms or risk factors for TB or LTBI, no further investigation or diagnostic testing is required. For all patients who are eligible by UNOS definitions, each OPO devises its own process for donor acceptance. The donor's medical and social history obtained by the OPO is made available for review by transplant center clinicians to independently assess risk for transmission of infection before accepting the organs for transplantation. The completeness and accuracy of this background information is variable, however, because often such information is obtained secondhand by interview of persons familiar with the donor.

Early recognition of posttransplantation TB in the recipient is critical for successful treatment. The incidence of TB among organ recipients is as much as 74 times that

of the general population (2). In addition, 49% of U.S. transplant recipients with TB have disseminated disease, and 38% die (2). Extrapulmonary and disseminated diseases are common, leading to atypical signs that might not be easily recognized as TB if unsuspected by the clinician. In transplant patients, TB should be considered in the differential diagnosis of persistent fever, pneumonia, meningitis, septic arthritis, pyelonephritis, septicemia, graft rejection, or bone marrow suppression. Clinicians should recognize that the presence of an unusual constellation of symptoms, particularly during the first few weeks after transplantation, raises the possibility of donor-transmitted infection or activation of LTBI. Even with a high index of suspicion, TB in an organ recipient can be challenging to diagnose: 75%-80% of organ recipients who developed TB had a false-negative pretransplantation TST (6), and in this immunosuppressed population, symptoms of TB might be attributed to other potential complications, including organ rejection or other infectious diseases.

Diagnosis of TB in an organ recipient, in the absence of clear risk factors or other evidence from pretransplantation screening, should prompt investigation of possible transmission from the donor. Other recipients from a common donor might be at risk and should be evaluated for TB. When transplantation-transmitted TB is suspected, healthcare providers should alert the associated OPO, tissue bank, and public health authorities.

To prevent TB transmission by transplantation, specific policies can be established to improve recognition of disease in donors. In 2004, the American Society of Transplantation developed guidelines to assist in pretransplantation screening of potential organ donors and recipients (6,7). These recommendations are not mandatory standards and, therefore, are not necessarily incorporated into OPO standard operating procedures. OPOs can enhance their pretransplantation screening protocols by incorporating these guidelines to identify risk factors for unrecognized TB in the donor. If risk factors are found, further mycobacterial testing and radiologic assessment is warranted. For risk factor assessment, OPOs should obtain donor history of symptoms consistent with active TB, past diagnosis of TB infection (active or latent), homelessness, excess alcohol or injection-drug use, incarceration, recent exposure to persons with active TB, or travel to areas where TB is endemic. Complete donor medical and social histories should be provided to transplant centers.

Regardless of risk factor assessment, testing for *M. tuberculosis* (e.g., AFB smear or mycobacterial culture) whenever clinical specimens for routine bacterial testing are obtained from donors can help ensure detection of

unrecognized TB. In addition, routine retention of samples of donor tissues and serum from organ procurement (or from autopsy) that are suitable for laboratory evaluation can aid subsequent transmission investigations. Genotyping and other relatedness testing of isolates can help establish or rule out transmission links between donor and recipients, as demonstrated in this report. OPOs also should follow up on results of all tests pending at the time of organ donation and notify transplant centers immediately of any results that might have implications for recipients. Because not all disease transmission through transplantation can be prevented, rapid recognition is critical to facilitate appropriate treatment, minimize complications, enhance patient safety, and improve public health.

#### **Acknowledgments**

This report is based, in part, by contributions by B Baker, MPH, S Pennington, Oklahoma City, P Lindsey, MD, C Harvey, DO, Oklahoma State Dept of Health Tuberculosis Div, S Mallonee, MPH, Oklahoma State Dept of Health, M Spinner, P Eddington, Oklahoma City County Tuberculosis Control Center; M Lambert, Cleveland County Health Dept; C Wallace, PhD, P Cruise, Texas Dept of State Health Svcs, K Finkel, MD, A Wanger, PhD, Univ of Texas Medical School at Houston, M Abramsky, MD, Houston Dept of Health and Human Svcs, S Haidry, MD, Galveston County Health District, B Seaworth, MD, Heartland National Tuberculosis Center, San Antonio; E Desmond, PhD, California Dept of Health Svcs; J Hager, MPH, United Network for Organ Sharing, Richmond, Virginia; D Seem, MPH, Div of Healthcare Quality Promotion, National Center of Preparedness, Detection, and Control of Infectious Diseases, V Tomlinson, MPA, P Moonan, DrPH, Div of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.

#### References

- Organ Procurement and Transplantation Network. Transplant data [Database]. Richmond, VA: Organ Procurement and Transplantation Network; 2008. Available at http://www.optn.org/data.
- Singh N, Paterson DL. Mycobacterium tuberculosis infection in solidorgan transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266–77.
- 3. Delmonico F. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infec Dis 2000;31:781–6.
- Wilck M, Fishman J. The challenges of infection in transplantation: donor-derived infections. Curr Opin Organ Transplant 2005;10:301–6.
- United Network for Organ Sharing. Minimum procurement standards for an organ procurement organization (OPO). Richmond, VA: United Network for Organ Sharing; 2001. Available at http://www.unos.org/ policiesandbylaws/policies.asp.
- American Society of Transplantation. Mycobacterium tuberculosis. Am J Transplant 2004;4(Suppl 10):S37–41. Available at http://www.black well-synergy.com/toc/ajt/4/s10.
- 7. American Society of Transplantation. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004;4 (Suppl 10):S10–20. Available at http://www.blackwell-synergy.com/toc/ajt/4/s10.

# Nonfatal Maltreatment of Infants — United States, October 2005–September 2006

During October 2005-September 2006 (federal fiscal year 2006), approximately 905,000 U.S. children were victims of maltreatment that was substantiated by state and local child protective services (CPS) agencies (1).\* Approximately 19% of child maltreatment fatalities occurred among infants (i.e., persons aged <1 year) (1), and homicide statistics suggest that fatality risk might be greatest in the first week of life (2). However, the risk for nonfatal maltreatment among infants has not been examined previously at the national level. To determine the extent of nonfatal infant maltreatment in the United States, CDC and the federal Administration for Children and Families (ACF) analyzed data collected in fiscal year 2006 (the most recent data available) from the National Child Abuse and Neglect Data System (NCANDS). This report summarizes the results of that analysis, which indicated that, in fiscal year 2006, a total of 91,278 infants aged <1 year (rate: 23.2 per 1,000 population) experienced nonfatal maltreatment, including 29,881 (32.7%) who were aged ≤1 week. Neglect was the maltreatment category cited for 68.5% of infants aged ≤1 week, but NCANDS data did not permit further characterization of the nature of this neglect. Developing effective measures to prevent maltreatment of infants aged ≤1 week will require more detailed characterization of neglect in this age group.

NCANDS is a national data collection and analysis system created in response to the federal Child Abuse Prevention and Treatment Act.† Data have been collected annually from states and reported since 1993. States submit caselevel data as child-specific records for each report of alleged child maltreatment for which a completed investigation or assessment by a CPS agency has been made during the reporting period. Individual CPS agencies are responsible for determining the type of maltreatment and outcome of the maltreatment investigation based on state and federal laws. However, no standardized definitions of maltreatment are used consistently by all states; therefore, each state maps its own classification of maltreatment onto NCANDS

<sup>\*</sup>Substantiated maltreatment is defined as maltreatment by a parent or other caregiver deemed to have occurred after thorough investigation by a qualified staff member from a CPS agency with jurisdiction over the geographic area in which the maltreatment took place. Additional information is available at http://www.acf.hhs.gov/programs/cb/pubs/cm05/index.htm.

<sup>&</sup>lt;sup>†</sup> Public Law 93-247 as amended. Additional information is available at http://www2.acf.hhs.gov/programs/cb/laws\_policies/cblaws/capta/index.htm.


definitions<sup>§</sup> before sending the final data file to NCANDS. Once a state submits its data to NCANDS, a technical validation review is conducted by a staff supervised by the ACF Children's Bureau to assess the internal consistency of the data and to identify probable causes for missing data. States are requested to make corrections as needed.

In fiscal year 2006, 49 states, the District of Columbia, and Puerto Rico provided case-level data to NCANDS. For this report, data from five states (Alaska, Maryland, North Dakota, Pennsylvania, and Vermont) were not available for analysis. Only data regarding victims with a CPS agency disposition of substantiated maltreatment issued during fiscal year 2006 were analyzed. Among the approximately 3.6 million children aged <18 years who were subjects of maltreatment investigations in fiscal year 2006, maltreatment was substantiated by CPS agencies in approximately 905,000 (25.1%) children. Substantiated maltreatment data were analyzed for victims aged <1 year by the age of the infant victim at the time of first report, sex, race/ethnicity, type of maltreatment, and source of the report.

A total of 91,278 unique victims of substantiated maltreatment were identified in CPS agency dispositions in fiscal year 2006 among infants aged <1 year, an annual rate of 23.2 per 1,000 population. A total of 47,117 (51.6%) victims were male. By race/ethnicity, 39,768 (43.6%) infant victims were white; 23,008 (25.2%) were black or African American; 17,582 (19.3%) were Hispanic; 1,141 (1.3%) were American Indian or Alaska Native; and 583 (0.6%) were Asian. Multiple race/ethnicity was identified for 2,874 (3.1%) of the infant victims, and 6,322 (6.9%) were of unknown race/ethnicity.

Among the 91,278 infant victims of substantiated maltreatment, 35,455 (38.8%) were aged  $\leq 1$  month (Figure 1). Of these, 29,881 (84.3%) were aged  $\leq 1$  week (Figure 2). Among maltreated infants aged  $\leq 1$  week, 20,472 (68.5%) were categorized as victims of neglect (including deprivation of necessities or medical neglect), and 3,957 (13.2%) as victims of physical abuse (Table).


FIGURE 1. Number of infants aged <1 year who were victims of substantiated maltreatment,\* by age in months — National Child Abuse and Neglect Data System, United States, October 2005–September 2006†



\* Defined as maltreatment by a parent or other caregiver deemed to have occurred after thorough investigation by a qualified staff member from a child protective services agency with jurisdiction over the geographic area in which the maltreatment took place. Additional information available at http://www.acf.hhs.gov/programs/cb/pubs/cm05/index.htm.

† Data from five states (Alaska, Maryland, North Dakota, Pennsylvania, and Vermont) were not available for analysis.

FIGURE 2. Number of infants aged ≤1 month who were victims of substantiated maltreatment,\* by age in days — National Child Abuse and Neglect Data System, United States, October 2005–September 2006<sup>†</sup>



\* Defined as maltreatment by a parent or other caregiver deemed to have occurred after thorough investigation by a qualified staff member from a child protective services agency with jurisdiction over the geographic area in which the maltreatment took place. Additional information available at http://www.acf.hhs.gov/programs/cb/pubs/cm05/index.htm.

Data from five states (Alaska, Maryland, North Dakota, Pennsylvania, and Vermont) were not available for analysis.

Among the 29,881 infant victims aged ≤1 week, 25,964 (86.9%) victims were reported to CPS agencies by professionals, including 19,486 (65.2%) by medical personnel and 5,542 (18.5%) by social services personnel (Table). Medical personnel also reported the greatest percentage (21,545 [60.8%]) of victims aged ≤1 month. Of infant victims aged <1 year, 29,462 (32.3%) were reported by medical personnel, followed by law enforcement personnel

SCategories of maltreatment in NCANDS are as follows: physical abuse, neglect or deprivation of necessities, medical neglect, sexual abuse, psychological or emotional maltreatment, other, and unknown. For this report, neglect or deprivation of necessities and medical neglect were combined into one category; other and unknown maltreatments also were combined into one category. Examples of neglect under the NCANDS categories include educational neglect, abandonment, fetal alcohol syndrome, and congenital drug exposure or addiction.

abandonment, retal alcohol syndrome, and congenital drug exposure or addiction.

Since 2003, NCANDS has used a method for compiling racial/ethnic data based on the 1997 revised Office of Management and Budget standards for race and ethnicity, which include the following racial categories: white, black or African American, Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander. In NCANDS, persons categorized as Hispanic or Latino are not categorized by race.

TABLE. Number and percentage of infants aged ≤1 week who were victims of substantiated maltreatment,\* by type of maltreatment and source of report — National Child Abuse and Neglect Data System, United States, October 2005–September 2006<sup>†</sup>

				Psychological or emotional	Other	
Source of report	Neglect <sup>§</sup>	Physical abuse	Sexual abuse	maltreatment	maltreatment <sup>¶</sup>	Total (%)
Professionals						
Medical personnel	13,456	2,845	12	39	3,134	19,486 (65.2)
Social services personnel	2,796	854	8	18	1,866	5,542 (18.5)
Mental health personnel	436	46	1	6	22	511 (1.7)
Legal, law enforcement, criminal justice personnel	208	23	3	3	60	297 (0.9)
Education personnel/ Day care providers/ Foster care providers	83	10	_	_	35	128 (0.4)
Total (%)	16,979 (56.8)	3,778 (12.6)	24 (0.1)	66 (0.2)	5,117 (17.1)	25,964 (86.9)
Community members/ Nonprofessionals						
Parents/Other relatives	220	27	2	3	72	324 (1.1)
Friends/Neighbors	185	11	1	_	18	215 (0.7)
Alleged perpetrators	2	_	_	_	1	3 (0.0)
Other/Unknown/ Anonymous reporters	3,086	141	2	8	138	3,375 (11.3)
Total (%)	3,493 (11.6)	179 (0.6)	5 (0.0)	11 (0.0)	229 (0.8)	3,917 (13.1)
Overall total (%)	20,472 (68.5)	3,957 (13.2)	29 (0.1)	77 (0.3)	5,346 (17.9)	29,881 (100)

<sup>\*</sup>Defined as maltreatment by a parent or other caregiver deemed to have occurred after thorough investigation by a qualified staff member from a child protective services agency with jurisdiction over the geographic area in which the maltreatment took place. Additional information available at \_http://www.acf.hhs.gov/programs/cb/pubs/cm05/index.htm.

Includes deprivation of necessities and medical neglect.

(19,574 [21.4%]), social services personnel (13,740 [15.1%]), parents/other relatives (8,058 [8.8%]), and friends/neighbors (2,927 [3.2%]).

Reported by: ML Brodowski, MSW, MPH, CM Nolan, MSW, Office on Child Abuse and Neglect; JA Gaudiosi, DBA, Data Team, Admin for Children and Families. YY Yuan, PhD, L Zikratova, MS, MJ Oritz, MA, MM Aveni, Walter R. McDonald and Associates, Inc., Sacramento, California. RT Leeb, PhD, TR Simon, PhD, WR Hammond, PhD, Div of Violence Prevention, National Center for Injury Prevention and Control, CDC.

Editorial Note: The findings in this report indicate that, in fiscal year 2006, 23.2 children per 1,000 population aged <1 year experienced substantiated nonfatal maltreatment in the United States. Among these infants, neglect was the maltreatment category most commonly cited, experienced by 68.5% of victims. Among infant victims aged <1 year who experienced substantiated maltreatment, 32.7% were aged ≤1 week, and 30.6% were aged <4 days. Neglect also was the maltreatment category most often cited among children aged ≤1 week.

This report is the first published national analysis of substantiated nonfatal maltreatment of infants, using NCANDS data. Although the results demonstrate a concentration of maltreatment and neglect at age ≤1 week, NCANDS data cannot be used to determine the etiology of the infant maltreatment and neglect because NCANDS

reports are limited to broad categories and do not provide specific information about diagnoses or the circumstances of the maltreatment. The concentration of reports of neglect in the first few days of life and the preponderance of reports from medical professionals during the same period suggest that neglect often was identified at birth. One hypothesis for the concentration of maltreatment and neglect reports in the first few days of life is that the majority of reports resulted from maternal or newborn drug tests. Although tracking of prenatal substance exposure and hospital postnatal toxicology-screening practices vary among states and within states, positive maternal or neonatal drug test results routinely are reported to CPS agencies as child neglect (3). Additional research is needed to clearly define the causes of substantiated neglect and maltreatment among newborns and to determine the best strategies for intervention.

The percentage of substantiated reports categorized as physical abuse among infants aged  $\leq 1$  week (13.2%) is similar to the percentage among maltreated children of all ages (16%) (*I*). Physical abuse is defined by CDC and NCANDS as the intentional use of physical force by a parent or caregiver against a child that results in, or has the potential to result in, physical injury. Physical abuse includes beating, kicking, biting, burning, shaking, or otherwise harming a child. Although the act is intentional,

Data from five states (Alaska, Maryland, North Dakota, Pennsylvania, and Vermont) were not available for analysis.

Includes infants who were victims of more than one type of maltreatment.

the consequence might be intentional or unintentional (i.e., resulting from overdiscipline or physical punishment) (1,4). One type of physical abuse, shaken baby syndrome/ abusive head trauma (SBS/AHT) (5), is a cause of severe physical injury and death in infants, occurring in 21.0–32.2 infants aged <1 year per 100,000 population. More detailed study of contextual information is needed to determine the causes of physical abuse in infants reported to NCANDS and to develop additional prevention strategies.

Few studies have examined rates and risk factors for maltreatment in infants aged <1 year, and risk for nonfatal maltreatment among infants has not been examined previously at the national level in the United States. A study by the Public Health Agency of Canada provided national-level data for that country (excluding the province of Quebec) and reported incidence in 2003 of substantiated nonfatal maltreatment among infants aged <1 year of 27.3 per 1,000 population for females and 29.1 for males,\*\* similar to the rates described in this report. Also similar to this study, the Canadian study found that neglect was the most common form of substantiated maltreatment for children aged <3 years; the Canadian study did not determine the most common form of maltreatment among infants aged <1 year.

The findings in this report are subject to at least two other limitations, in addition to the lack of specific information about maltreatment circumstances. First, underreporting or delayed reporting might influence the findings. Both mandated reporters and the public might lack sufficient knowledge or training that supports reporting possible child maltreatment (6,7). To assist health-care professionals in better reporting child maltreatment, CDC developed uniform definitions and recommended data elements to promote and improve consistency of child maltreatment reporting and serve as a technical reference for the collection of data (4). Second, data collection and reporting practices vary among states, and data from certain states were not available for analysis.

CDC supports a range of research, early intervention, and prevention programs at the national, state, and local levels. These efforts include a focus on developing child-maltreatment tracking programs in state health departments and promotion of positive parenting and prevention of child maltreatment through a framework of safe, stable, and nurturing relationships between children and caregivers. †† Similarly, ACF supports a range of prevention and intervention programs, including programs to identify and serve

substance-exposed newborns and reduce variation in the policies and procedures related to prenatal substance exposure. Reframing neglect as a series of missed opportunities for prevention and emphasizing safe, stable, and nurturing relationships can highlight opportunities for prevention that might otherwise be missed. For example, approximately 84% of pregnant women in the United States receive some prenatal care, and approximately 99% of infants are born in medical settings (8), these setting provide an opportunity for medical professionals to detect and manage early risk for maltreatment (e.g., maternal substance abuse) that can impair or interfere with child-caregiver relationships.

Serious injury resulting from physical abuse of infants can be decreased by efforts focusing on reduction of SBS/AHT through in-hospital programs aimed at parents of newborns. These programs have produced a substantial reduction in reported SBS/AHT in localized areas (9), and CDC is supporting research to evaluate the replicability of these results in diverse settings. In addition, home-visitation and parent-training programs (10), particularly those that 1) begin during pregnancy, 2) provide social support to parents, and 3) teach parents about developmentally appropriate infant behavior and age-appropriate disciplinary communication skills, have been determined to reduce risk for child maltreatment.

## **References**

- US Department of Health and Human Services, Administration on Children, Youth and Families. Child maltreatment 2006. Washington, DC: US Department of Health and Human Services; 2008. In press.
- CDC. Variation in homicide during infancy—United States, 1989– 1998. MMWR 2002;51:187–9.
- Birchfield M, Scully J, Handler A. Perinatal screening for illicit drugs: policies in hospitals in a large metropolitan area. J Perinatol 1995;15: 208–14.
- Leeb RT, Paulozzi L, Melanson C, Simon T, Arias I. Child maltreatment surveillance: uniform definitions for public health and recommended data elements, version 1.0. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.
- American Academy of Pediatrics, Committee on Child Abuse and Neglect. Shaken baby syndrome: rotational cranial injuries—technical report. Pediatrics 2001;108:206–10.
- 6. Levi BH, Brown G. Reasonable suspicion: a study of Pennsylvania pediatricians regarding child abuse. Pediatrics 2005;116:e5–12.
- Markenson D, Tunik M, Cooper A, et al. A national assessment of knowledge, attitudes, and confidence of prehospital providers in the assessment and management of child maltreatment. Pediatrics 2007;119:e103–8.
- 8. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2005. Natl Vital Stat Rep 2007;56(6).
- 9. Dias MS, Smith K, DeGuehery K, Mazur P, Li V, Shaffer ML. Preventing abusive head trauma among infants and young children: a hospital-based, parent education program. Pediatrics 2005;115: e470–7.
- 10. Bilukha O, Hahn RA, Crosby A, Task Force on Community Preventive Services. The effectiveness of early childhood home visitation in preventing violence: a systematic review. Am J Prev Med 2005;28(2 suppl 1):11–39.

<sup>\*\*</sup> Available at http://www.phac-aspc.gc.ca/cm-vee/csca-ecve/pdf/childabuse\_final\_e.pdf.

<sup>††</sup> Additional information available at http://www.childwelfare.gov/preventing, http://www.friendsnrc.org, and http://www.cdc.gov/ncipc/dvp/cmp/default.htm.

## Surveillance for Community-Associated Clostridium difficile — Connecticut, 2006

Clostridium difficile is a well-known cause of hospitalacquired infectious diarrhea and is associated with increased health-care costs, prolonged hospitalizations, and increased patient morbidity. Previous antimicrobial use, especially use of clindamycin or ciprofloxacin, is the primary risk factor for development of C. difficile-associated diarrhea (CDAD) because it disrupts normal bowel flora and promotes C. difficile overgrowth (1). Historically, CDAD has been associated with elderly hospital in-patients or longterm-care facility (LTCF) residents. Since 2000, a strain of C. difficile that has been identified as North American pulsed-field type 1 (NAP1) and produces an extra toxin (binary toxin) and increased amounts of toxins A and B has caused increased morbidity and mortality among hospitalized patients (2,3). During 2005, related strains caused severe disease in generally healthy persons in the community at a rate of 7.6 cases per 100,000 population, suggesting that traditional risk factors for C. difficile might not always be factors in development of community-associated CDAD (CA-CDAD) (4). Cases of CA-CDAD are not nationally reportable, and population-based data at a statewide level have not been reported previously. In 2006, the Connecticut Department of Public Health (DPH) implemented a statewide surveillance system to assess the burden of CA-CDAD and to determine the descriptive epidemiology, trends, and risk factors for this disease. This report describes that surveillance system and summarizes results from the first year of surveillance. The findings indicated the presence of occasionally severe CDAD among healthy persons living in the community, including persons with no established risk factors for infection. Clinicians should consider a diagnosis of CA-CDAD in outpatients with severe diarrhea, even in the absence of established risk factors. In addition, continued surveillance is needed to determine trends in occurrence and whether more toxigenic strains are having an increasing impact in the community and in the hospital setting.

On January 1, 2006, CA-CDAD was added to the list of conditions reportable by Connecticut health-care providers. A case of CA-CDAD was defined as a positive *C. difficile* toxin assay for a person with gastrointestinal symptoms and no known previous overnight hospitalizations or LTCF stays during the 3 months preceding specimen collection, collected from an outpatient or within 48 hours of hospital admission (5). DPH staff members contacted hospital infection-control practitioners at Connecticut's 32 acute-

care hospitals by telephone, informed them about the new reporting requirements, and asked them to review positive laboratory results to identify cases. Laboratories were not required to report to DPH. Physicians were informed by a special mailing. In May 2006, all hospitals were sent a letter summarizing initial findings and reminding physicians and infection-control practitioners about the reporting requirements. In addition, hospitals that did not initially report cases were recontacted by telephone and reminded of the reporting requirements. DPH staff members contacted treating physicians to confirm case status and collect patient information, including demographics, symptoms, select medical history, and possible risk factors. When necessary, DPH staff members reviewed medical records or conducted patient interviews. However, systematic patient interviews to verify absence of a recent stay in a health-care setting were not conducted.

Incidence rates were calculated using the number of confirmed cases reported among Connecticut residents and 2005 U.S. Census state population estimates. Differences in proportions and tests for trend by age group were evaluated using the chi-square test and chi-square test for trend; multivariate logistic regression analysis was conducted. A separate 3-month pilot study was conducted during 2006 by FoodNet,\* Emerging Infections Program sites,† and CDC to collect specimens from patients with CA-CDAD for culture for *C. difficile* and to characterize the isolates by toxinotyping and detection of binary toxin and deletions in the *tcd*C gene (6). As part of this study, in Connecticut, all toxin-positive stool specimens from confirmed CA-CDAD patients at three hospital laboratories were collected and cultured.

A total of 456 possible cases, determined on the basis of tests conducted on outpatients or within 2 days of hospitalization, were reported during 2006; 241 (53%) were subsequently confirmed as meeting the case definition. Of the 215 cases that were not confirmed, 159 (74%) occurred in persons who had an LTCF stay or hospitalization during the preceding 3 months, 50 (23%) occurred in per-

<sup>\*</sup>The Foodborne Diseases Active Surveillance Network (FoodNet) is the principal foodborne and enteric disease surveillance component of CDC's Emerging Infections Program (EIP). FoodNet is a set of population-based surveillance projects for laboratory-confirmed disease collaboratively undertaken by CDC, 10 EIP sites (Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, Tennessee, and selected counties in California, Colorado, and New York), the U.S. Department of Agriculture, and the Food and Drug Administration.

<sup>&</sup>lt;sup>†</sup> The CDC Emerging Infections Program supports population-based surveillance in 10 sites in the United States. Each site is based in a state health department, often with a local academic center partner, working in collaboration with local health departments, public health laboratories, clinical laboratories, infection-control practitioners, health-care providers, and hospitals to assess the public health impact of emerging infections and evaluate methods for their prevention and control.

sons for whom insufficient medical information was available to enable confirmation; and six (<1%) were in persons who were asymptomatic The overall annual 2006 incidence of CA-CDAD was 6.9 cases per 100,000 population, with similar rates found in most counties. Incidence among those aged  $\geq$ 5 years increased with age; females had nearly twice the incidence of males. Rates were higher during the spring and summer months than during the fall and winter months (Table 1).

A total of 28 (88%) of 32 acute-care hospitals reported at least one case of CA-CDAD (range: 1–26 cases). Among the 241 cases, 110 (46%) were in patients who required hospitalization for CA-CDAD, mainly for diagnosis and treatment of dehydration or colitis; 13 (12%) were in patients who required an intensive-care unit stay, two (2%) were in patients who had both toxic megacolon and a colectomy, and two (2%) were in patients who died of complications related to *C. difficile* infection. The median length of stay among hospitalized patients was 4 days (range: 1–39 days).

Among all patients for whom follow-up information was available, 29% had an inpatient health-care exposure (defined as overnight hospitalization or LTCF stay during the >3 to 12 months preceding illness or day surgery during the 12 months preceding illness), 67% had an underlying medical condition, and 68% had taken an antimicrobial during the 3 months preceding symptom onset (Table 2). When CA-CDAD patients requiring hospitalization were compared with those managed as outpatients, independent predictors of hospitalization by multivariate analysis included age of  $\geq$ 65 years (p = 0.001), fever (p = 0.001), and inpatient health-care exposure during the >3 to 12 months preceding illness (p = 0.04).

A total of 59 (25%) patients had no underlying conditions and no inpatient health-care exposures during the 12 months preceding illness. Compared with all other patients, this group was younger (63% versus 23% were aged <45 years [p<0.0001]), less likely to be hospitalized for their CA-CDAD illness (36% versus 52% [p<0.04]), and more likely to report bloody diarrhea (37% versus 19%

TABLE 1. Number, percentage, and rate\* of community-associated *Clostridium difficile*–associated disease cases,† by selected characteristics — Connecticut, 2006

Characteristic	No.	(%)	Rate	RR§ (95% CI <sup>¶</sup> )	p value
Age of patient (yrs)					
0-4	13	(5)	6.2	5.8 (2.0–16.3)	
5–14	5	(2)	1.1	Referent	
15–24	11	(5)	2.4	2.2 (0.8–6.4)	
25–44	56	(23)	5.9	5.5 (2.2–13.8)	
45-64	76	(32)	8.2	7.7 (3.1–19.1)	
<u>≥</u> 65	80	(33)	16.9	15.9 (6.5–39.3)	<0.0001**
Sex of patient					
Male	80	(33)	4.7	Referent	
Female	161	(67)	8.9	1.9 (1.5–2.5)	< 0.0001
County of residence (population)					
Fairfield (902,775)	62	(26)	6.9		
Hartford (877,373)	63	(26)	7.2		
New Haven (846,776)	40	(17)	4.7		
New London (266,618)	16	(7)	6.0		
Litchfield (190,071)	16	(7)	8.4		
Middlesex (163,214)	5	(2)	3.1		
Tolland (147,634)	28	(12)	19.0		
Windham (115,826)	11	(4)	9.5		
Months/Seasons					
January-March	50	(21)	1.4		
April–June	79	(33)	2.3		
July-September	72	(30)	2.1		
October-December	40	(16)	1.1		
Fall/Winter (October-March)	90	(37)	2.6	Referent	
Spring/Summer (April-September)	151	(63)	4.3	1.7 (1.3–2.2)	< 0.0001
Total	241	(100)	6.9		

<sup>\*</sup> Per 100,000 population. Based on 2005 U.S. Census data.

<sup>&</sup>lt;sup>†</sup> A case was defined as a positive *C. difficile* toxin assay for a person with gastrointestinal symptoms and no known previous overnight hospitalizations or long-term–care facility stays during the 3 months preceding specimen collection, collected from an outpatient or within 48 hours of hospital admission.

<sup>§</sup> Relative risk.

<sup>¶</sup> Confidence interval.

<sup>\*\*</sup> Chi-square test for linear trend for 5-14 years age group and older.

TABLE 2. Clinical features and predisposing risk factors among patients with community-associated *Clostridium difficile*—associated disease\* — Connecticut, 2006

Characteristic	No.	(%)
Clinical features		
Abdominal pain (n = 222)	169	(76)
Vomiting (n = 221)	50	(23)
Diarrhea <sup>†</sup> (n = 236)	227	(96)
Bloody diarrhea (n = 209)	48	(23)
Fever <sup>§</sup> (n = 203)	56	(28)
Predisposing risk factors		
Previous health-care exposure (n = 214)	63	(29)
Overnight hospitalization or long-term-care		
facility stay during preceding >3 to 12 months		
(n = 222)	34	(15)
Day surgery during preceding 12 months		
(n = 217)	36	(17)
Underlying medical condition (comorbid		
condition) (n = 220)	147	(67)
Any antibiotic use during 3 months preceding		
symptom onset (n = 227)	154	(68)
Clindamycin (n = 121)	19 <sup>¶</sup>	(16)
Fluoroquinolones (n = 121)	42¶	(35)
Other** (n = 121)	54¶	(45)

- \* A case was defined as a positive *C. difficile* toxin assay for a person with gastrointestinal symptoms and no known previous overnight hospitalizations or long-term–care facility stays during the 3 months preceding specimen collection, collected from an outpatient or within 48 hours of hospital admission.
- † Median number of stools per day was six (range: 1-30).
- § Documented as a temperature >100.4°F (>38.0°C).
- ¶ Among those with reported antibiotic use; 33 patients used antibiotics but were unable to specify type.
- \*\* Includes cephalosporins, tetracycline, macrolides, and metronidazole.

[p=0.01]). In addition, 35 (59%) patients received an antimicrobial during the 3 months preceding symptom onset, 21 (36%) took no antimicrobial, and three (5%) patients had no information on antimicrobial use available.

Twelve *C. difficile* isolates were recovered from toxin-positive stool specimens and were characterized at CDC. Eight (67%) had binary toxin genes similar to the epidemic NAP1 strain, and three (25%) were identified as NAP1.

Coinfection with a second pathogen appeared to be rare. A review of the FoodNet enteric pathogen surveillance database in Connecticut indicated that five (2%) of the 241 patients with CA-CDAD also had a stool-culture positive result for another reportable enteric pathogen from a specimen collected on the same day or within 1 day of the toxin-positive *C. difficile* sample: *Salmonella* (one patient), *Campylobacter* (three), and *Escherichia coli* O157:H7 (one).

**Reported by:** T Rabatsky-Ehr, MPH, K Purviance, MPH, D Mlynarski, MPH, P Mshar, MPH, J Hadler, MD, Epidemiology and Emerging Infections Program, Connecticut Dept of Public Health. L Sosa, MD, EIS Officer, CDC.

Editorial Note: The findings in this report demonstrate that CA-CDAD is an important and geographically widespread health problem among Connecticut outpatients, a

population previously thought to be at low risk for this disease. Although interest in CA-CDAD has grown in recent years, this report describes the first attempt to define population-based incidence of this disease at the state level. The CA-CDAD incidence in Connecticut in 2006 (6.9 per 100,000 population) was similar to that found in Philadelphia in 2005 (7.6 per 100,000 population) using a similar case definition. Both of these rates were considerably lower than that found in the United Kingdom (UK) in 2004 (22.0 per 100,000 population), despite the fact the UK study used a more restrictive case definition in which persons with hospitalization during the 12 months preceding illness onset were excluded (4,7).

The findings in this report highlight the importance of increasing age (with the attendant underlying health problems and increased use of the health-care system) and antibiotic exposure in the development of CDAD. However, one fourth of all CA-CDAD cases were in persons who lacked established predisposing risk factors for CDAD, including advanced age, an underlying health condition, and a health-care exposure during the 12 months preceding illness. Moreover, similar to what was observed in the community studies conducted in Philadelphia and the UK, 32% of patients had no recent exposure to antimicrobials. Approximately 9% of all cases were in patients who had none of these factors. These findings emphasize the need for continued study of this disease to identify additional risk factors for exposure to C. difficile and for development of disease.

The ability of *C. difficile* to form spores is thought to be a key feature in enabling the bacteria to persist in patients and the physical environment for long periods, thereby facilitating its transmission. *C. difficile* is transmitted through the fecal-oral route. Postulated risk factors for acquiring *C. difficile* in the community include contact with a contaminated health-care environment, contact with persons who are infected with and shedding *C. difficile* (person-to-person transmission), and ingestion of contaminated food.

Studies have shown *C. difficile* to be a pathogen or colonizer of calves, pigs, and humans (8,9). The recent detection of the NAP1 strain of *C. difficile* in retail ground beef is cause for concern (9). This hyper–toxin-producing strain has been reported as a cause of serious outbreaks of health-care—associated disease in humans in North America and Europe (10) and was found among a small subset of specimens from CA-CDAD cases in Connecticut. Further studies are needed to determine whether *C. difficile* is transmitted via the food chain and the relative importance of such transmission in human CDAD.

The findings in this report are subject to at least four limitations. First, measured incidence is subject to the limitations of the toxin-detection assays usually used for diagnosis of C. difficile. These assays can be insensitive (i.e., 65%–90% sensitivity) and nonspecific; in addition, 1%– 2% of persons tested with the most widely used toxin assays might test positive in the absence of infection. Because C. difficile is difficult and labor-intensive to isolate, culture usually is only used when a clinical need for verification of a positive toxin assay exists. Second, because systematic patient interviews were not conducted, some patients might have had recent health-care exposures that were not recorded in available medical records, leading to potential misclassification of health-care-associated cases as CA-CDAD. Third, underreporting might have occurred because laboratories were not required to report and no validation or assessment of completeness of reporting was conducted. Finally, because cultures were not routinely collected for isolation and molecular characterization of organisms, the extent to which recently described emerging strains are causing disease in Connecticut or are responsible for illness in persons without established risk factors for CA-CDAD is unknown.

Future CA-CDAD surveillance measures in Connecticut will focus on collecting detailed information on hospitalized patients for whom more complete medical records are available. Continued population-based surveillance is necessary to monitor trends and describe the extent of CA-CDAD and possible risk factors. Although CA-CDAD surveillance systems are resource intensive, other states should consider implementing these systems to assess trends in CA-CDAD and to help health-care providers become more aware of this emerging problem.

#### **Acknowledgments**

This report is based, in part, on data contributed by the Yale University Emerging Infections Program, New Haven; laboratory staff members at the Hospital of St. Raphael, New Haven, Connecticut; and members of CDC's FoodNet.

## References

- 1. Barbut F, Petit JC. Epidemiology of *Clostridium difficile*-associated infections. Clin Microbiol Infect 2001;7:405–10.
- McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005;353: 2433–41.
- Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–9.
- CDC. Severe Clostridium difficile—associated disease in populations previously at low risk—four states, 2005. MMWR 2005;54:1201–5.
- McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of *Clostridium difficile*associated disease. Infect Control Hosp Epidemiol 2007;28:140–5.

- Rupnik M, Avensani V, Jane M, Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of *Clostridium difficile*. J Clin Microbiol 1998;36:2240–7.
- Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acidsuppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. JAMA 2005;294:2989–95.
- 8. Rodriguez-Palacios A, Staempfli H, Duffield T, et al. *Clostridium difficile* PCR ribotypes in calves, Canada. Emerg Infect Dis 2006;12:1730–6.
- Rodriguez-Palacios A, Staempfli HR, Duffielf T, Weese JS. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007;13: 485–7.
- 10. Warny M, Pepin J, Fang A, et al. Toxin-production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. Lancet 2005;336:1079–84.

## Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24–59 Months Who Are Not Completely Vaccinated

This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration.\* In February 2000, PCV7, marketed as Prevnar® and manufactured by Wyeth Vaccines (Collegeville, Pennsylvania), was approved by the Food and Drug Administration for use in infants and young children. At that time, the Advisory Committee on Immunization Practices (ACIP) recommended that children aged 24-59 months who have certain underlying medical conditions or are immunocompromised receive PCV7. In addition, ACIP recommended that PCV7 be considered for all other children aged 24-59 months, with priority given to those who are American Indian/Alaska Native or of African-American descent, and to children who attend group day care centers (1). The recommendation also provided schedules for administering PCV7 to children aged 24-59 months who were either unvaccinated or who had a lapse in PCV7 administration; these schedules included 1) 1 dose of PCV7 for healthy children, and 2) 2 doses of PCV7 ≥2 months apart for children with certain chronic diseases or immunosuppressive conditions (1).

<sup>\*</sup>PCV7 is recommended for routine administration as a 4-dose series for infants at ages 2, 4, 6, and 12–15 months. Catch-up immunization is recommended for children aged ≤23 months, using fewer doses depending on age at the time of first vaccination.

ACIP's rationale for limiting the recommendation for routine vaccination to children aged 24–59 months who have certain underlying medical conditions or are immunocompromised was concern about limited vaccine supply and cost. Since September 2004, PCV7 has not been in short supply (2). Additionally, certain health-care providers have found the permissive recommendation for healthy children aged 24–59 months to be confusing. The ACIP Pneumococcal Vaccines Work Group reviewed data on safety and immunogenicity of PCV7 in children aged 24–59 months, current rates of PCV7-type invasive disease, vaccination coverage rates, and post-licensure vaccine effectiveness. In October 2007, on the basis of that review, ACIP approved the following revised recommendation for use of PCV7 in children aged 24–59 months†:

- For all healthy children aged 24–59 months who have not completed any recommended schedule for PCV7, administer 1 dose of PCV7.
- For all children with underlying medical conditions aged 24–59 months who have received 3 doses, administer 1 dose of PCV7.
- For all children with underlying medical conditions aged 24–59 months who have received <3 doses, administer 2 doses of PCV7 at least 8 weeks apart.

No changes were made to previously published recommendations regarding 1) the use of PCV7 in children aged 2–23 months, 2) the list of underlying medical or immunocompromising conditions, or 3) the use of 23-valent pneumococcal polysaccharide vaccine in children aged  $\geq 2$  years who have previously received PCV7 (3).

## References

- 1. CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR 2000;49(No. RR-9).
- CDC. Pneumococcal conjugate vaccine shortage resolved. MMWR 2004;53:851–2.
- 3. CDC. Recommended immunization schedules for persons aged 0–18 years—United States, 2008. MMWR 2008;57(1):Q1–4.

## Notice to Readers

## National Child Abuse Prevention Month — April 2008

April is National Child Abuse Prevention Month, an observance intended to increase awareness of child maltreatment and encourage individuals and communities to support children and families. CDC defines child maltreatment as any act or series of acts of commission or omission by a parent or other caregiver that results in harm, potential for harm, or threat of harm to a child (1).

During April, CDC and the federal Administration for Children and Families (ACF) will highlight a range of child maltreatment prevention measures at the national, state, and local levels, including promotion of safe, stable, and nurturing relationships (SSNR) between children and caregivers. Three CDC publications support the SSNR framework: 1) Child Maltreatment Surveillance, Uniform Definitions for Public Health and Recommended Data Elements; 2) The Effects of Childhood Stress on Health Across the Lifespan; and 3) Preventing Child Sexual Abuse within Youth Serving Organizations: Getting Started on Policies and Procedures.

These publications and additional information regarding child maltreatment are available at http://www.cdc.gov/injury. Additional information from ACF is available at http://www.acf.hhs.gov and from the Child Welfare Information Gateway at http://www.childwelfare.gov.

#### Reference

Leeb RT, Paulozzi L, Melanson C, Simon T, Arias I. Child maltreatment surveillance: uniform definitions for public health and recommended data elements, version 1.0. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.

<sup>&</sup>lt;sup>†</sup> The minimum interval between all doses of PCV7 for children aged 24–59 months is 8 weeks.

## Notice to Readers

# National Public Health Week — April 7–13, 2008

Since 1995, the first full week of April has been designated in the United States as National Public Health Week. This year's observance focuses on climate change and public health. During April 7–13, 2008, CDC, the American Public Health Association, and members of the public health community will conduct activities and host events that encourage the public, policy-makers, and public health professionals to take steps that will have positive effects on their individual health, the health of the nation, and the climate.

In conjunction with the observance, CDC has developed resources and a list of actions that public health agencies can take to respond to potential health effects of climate change. Additional information regarding climate change and National Public Health Week is available at http://www.cdc.gov/nceh/climatechange and http://www.nphw.org.

## Notice to Readers

## New Public Health Emergency Law and Forensic Epidemiology Training Materials Released

CDC's Public Health Law Program has released version 3.0 of its Public Health Emergency Law and Forensic Epidemiology training materials on CD-ROM. These self-contained training packages were developed for use by instructors in any jurisdiction in the United States to provide public health preparedness training to front-line practitioners.


Public Health Emergency Law is designed to help public health practitioners and emergency management professionals improve their understanding of the use of law as a public health tool. Forensic Epidemiology is designed to help public health and law enforcement agencies strengthen coordination of responses to pandemic influenza and similar threats. Materials include a new CDC-developed case study on pandemic influenza.

Information regarding ordering a free CD-ROM with the two sets of training materials is available at http://www2.cdc.gov/phlp/phel.asp. Additional information is available via e-mail at fe-phel@mcking.com.

# **QuickStats**

## FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

# Life Expectancy Ranking\* at Birth,† by Sex — Selected Countries and Territories, 2004<sup>§¶</sup>



\* Rankings are from the highest to lowest female life expectancy at birth.

<sup>†</sup> Life expectancy at birth represents the average number of years that a group of infants would live if the infants were to experience throughout life the age-specific death rates present at birth.

<sup>¶</sup> Most recent data available. Data for Ireland and Italy are for 2003.

In 2004, life expectancy at birth ranged from a low of 59.1 years for the Russian male population to a high of 85.6 years for the female population of Japan. In the United States, life expectancy for men (75.2 years) ranked 25th out of 37 countries and territories and 23rd for women (80.4 years). Japan and Hong Kong were the countries with the highest life expectancy, whereas the countries of Eastern Europe (e.g., Russian Federation, Romania, and Bulgaria) reported the lowest life expectancy.

**SOURCES:** Organisation for Economic Co-operation and Development. OECD health data 2007: statistics and indicators for 30 countries. Paris, France: Organisation for Economic Co-operation and Development; 2008. Available at http://www.oecd.org/health/healthdata.

CDC. Health, United States, 2007. With chartbook on trends in the health of Americans. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2007. Available at http://www.cdc.gov/nchs/data/hus/hus07.pdf.

<sup>§</sup> Countries and territories were selected based on quality of data, high life expectancy, and a population of at least 1 million population. Differences in life expectancy reflect differences in reporting methods, which can vary by country, and actual differences in mortality rates.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending March 29, 2008 (13th Week)\*

	Current	Cum	5-year weekly	Total	cases rep	orted for	previous	s years	
Disease	week	2008	average <sup>†</sup>	2007	2006	2005	2004	2003	States reporting cases during current week (No.)
Anthrax	_			_	1	_	_	_	
Botulism:									
foodborne	_	1	0	26	20	19	16	20	
infant	_	13	1	83	97	85	87	76	
other (wound & unspecified)	_	1	0	24	48	31	30	33	
Brucellosis	_	10	2	128	121	120	114	104	
Chancroid	_	13	1	30	33	17	30	54	
Cholera	_	_	0	7	9	8	6	2	
Cyclosporiasis§	2	16	1	91	137	543	160	75	FL (2)
Diphtheria	_	_	_	_	_	_	_	1	. ,
Domestic arboviral diseases <sup>§,1</sup> :									
California serogroup	_	_	0	44	67	80	112	108	
eastern equine	_	_	_	4	8	21	6	14	
Powassan	_	_	_	1	1	1	1	_	
St. Louis	_	_	0	7	10	13	12	41	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis§,**:									
Ehrlichia chaffeensis	_	22	2	734	578	506	338	321	
Ehrlichia ewingii	_	1	_	_	_	_	_	_	
Anaplasma phagocytophilum	_	6	2	730	646	786	537	362	
undetermined	_	1	1	162	231	112	59	44	
Haemophilus influenzae,††									
invasive disease (age <5 yrs):									
serotype b	1	8	0	23	29	9	19	32	MN (1)
nonserotype b	1	34	3	174	175	135	135	117	NV (1)
unknown serotype	4	58	4	190	179	217	177	227	OH (1), NC (1), TN (1), AZ (1)
Hansen disease§	_	16	2	73	66	87	105	95	- ( ) - ( ) ( ) ( )
Hantavirus pulmonary syndrome§	_	2	0	32	40	26	24	26	
Hemolytic uremic syndrome, postdiarrheal§	1	14	2	276	288	221	200	178	CO(1)
Hepatitis C viral, acute	5	135	17	847	766	652	720	1,102	MO (1), KS (1), TX (2), WA (1)
HIV infection, pediatric (age <13 yrs) <sup>§§</sup>	_	_	4	_	_	380	436	504	
Influenza-associated pediatric mortality <sup>§,¶¶</sup>	6	59	1	76	43	45	_	N	CT (1), MN (2), TX (1), AZ (1), NV (1)
Listeriosis	5	99	10	783	884	896	753	696	FL(5)
Measles***	_	7	1	42	55	66	37	56	( )
Meningococcal disease, invasive†††:									
A, Č, Y, & W-135	1	69	8	305	318	297	_	_	MN (1)
serogroup B	3	42	3	149	193	156	_	_	NY (2), MN (1)
otherserogroup	_	11	0	31	32	27	_	_	
unknown serogroup	14	169	19	581	651	765	_	_	NY (1), OH (1), FL (1), CO (1), CA (10)
Mumps	7	140	67	777	6,584	314	258	231	TN (1), NV (1), CA (5)
Novel influenza A virus infections	_	_	_	1	N	N	N	N	
Plague	_	_	_	6	17	8	3	1	
Poliomyelitis, paralytic	_	_	_	_	_	1	_	_	
Poliovirus infection, nonparalytic§	_	_	_	_	N	N	N	N	
Psittacosis§	_	1	0	11	21	16	12	12	
Q fever <sup>§,§§§</sup> total:	_	10	2	190	169	136	70	71	
acute	_	7	_	_	_	_	_	_	
chronic	_	3	_	_	_	_	_	_	
Rabies, human	_	_	_	_	3	2	7	2	
Rubella	1	2	0	11	11	11	10	7	PA (1)
Rubella, congenital syndrome	_	_	0	_	1	1	_	1	• *
SARS-CoV <sup>§,****</sup>	_	_	0	_	_	_	_	8	

<sup>-:</sup> No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

\* Incidence data for reporting years 2007 and 2008 are provisional, whereas data for 2003, 2004, 2005, and 2006 are finalized.

<sup>†</sup> Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.

§ Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases

<sup>§</sup> Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 \*\* The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories:

<sup>\*\*</sup> The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).

†† Data for *H. influenzae* (all ages, all serotypes) are available in Table II.

SS Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.

<sup>11</sup> Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Fifty-nine cases occurring during the 2007–08 influenza season have been reported.

<sup>\*\*\*</sup> No measles cases were reported for the current week.

<sup>††††</sup> Data for meningococcal disease (all serogroups) are available in Table II.

<sup>§§§</sup> In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.

The one rubella case reported for the current week was unknown.


<sup>\*\*\*\*</sup> Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending March 29, 2008 (13th Week)\*

	Current	Cum	5-year weekly	Total	cases rep	orted for	previous	years	
Disease	week	2008	average <sup>†</sup>	2007	2006	2005	2004	2003	States reporting cases during current week (No.)
Smallpox§	_		_		_	_	_	_	
Streptococcal toxic-shock syndrome§	3	26	4	104	125	129	132	161	PA (1), MN (2)
Syphilis, congenital (age <1 yr)	_	20	7	293	349	329	353	413	
Tetanus	1	1	0	23	41	27	34	20	NE (1)
Toxic-shock syndrome (staphylococcal)§	_	12	2	84	101	90	95	133	
Trichinellosis	_	2	0	6	15	16	5	6	
Tularemia	_	2	0	115	95	154	134	129	
Typhoid fever	3	69	5	380	353	324	322	356	PA (1), CA (2)
Vancomycin-intermediate Staphylococcus aure	eus§ —	1	0	27	6	2	_	N	
Vancomycin-resistant Staphylococcus aureus	<u> </u>	_	0	_	1	3	1	N	
Vibriosis (noncholera Vibrio species infections	)§ 5	30	1	361	N	N	N	N	FL (4), CA (1)
Yellow fever	_	_	_	_	_	_	_	_	

<sup>-:</sup> No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals March 29, 2008, with historical data



<sup>\*</sup> Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

## Notifiable Disease Data Team and 122 Cities Mortality Data Team Patsy A. Hall

Deborah A. Adams
Willie J. Anderson
Lenee Blanton
Rosaline Dhara
Carol Worsham
Pearl C. Sharp

<sup>\*</sup> Incidence data for reporting years 2007 and 2008 are provisional, whereas data for 2003, 2004, 2005, and 2006 are finalized.

<sup>†</sup> Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.

Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

(13th Week)*	Chlamydia <sup>†</sup> Previous						Coccid	ioidomyo	osis		Cryptosporidiosis				
	Current		vious veeks	Cum	Cum	Current		vious veeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	12,081	20,921	25,082	222,543	262,953	52	134	335	1,795	1,924	50	84	973	673	708
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	680 172 59 371 35 43	686 215 50 311 39 61 13	1,517 1,093 67 661 73 98 32	8,484 1,874 688 4,605 542 769 6	8,205 1,958 653 4,016 495 856 227	N N N —	0 0 0 0 0 0	1 0 0 0 1 0	1 N N N 1 —	N N N —	_ _ _ _ _	4 0 1 1 1 0	16 2 5 11 5 3 4	20 2 1 — 4 2 11	78 42 6 14 10 —
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	4,226 — 843 2,920 463	2,724 393 563 892 789	4,294 522 2,044 2,763 1,754	30,384 3,045 6,170 11,184 9,985	34,063 5,628 5,451 12,244 10,740	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	8 -6 - 2	10 1 3 1 6	117 7 20 10 103	100 3 28 15 54	81 4 17 22 38
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	787 1 278 383 125	3,394 1,009 392 704 860 380	6,191 2,209 651 1,002 3,617 607	33,951 8,140 4,843 9,637 7,122 4,209	44,698 12,499 5,442 10,065 11,674 5,018	N N — — N	1 0 0 0 0	3 0 0 2 1 0	7 N N 4 3 N	11 N N 9 2 N	5 — — 5 —	20 2 2 4 5 7	134 13 41 11 60 59	156 12 16 40 54 34	156 23 9 33 46 45
W.N. Central lowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	397 123 191 7 — 11 — 65	1,201 162 149 260 459 88 32 52	1,462 251 393 318 551 183 65 81	13,361 2,153 1,528 2,859 4,780 1,008 347 686	15,666 2,166 2,011 3,374 5,812 1,261 443 599	N N N N N N N N	0 0 0 0 0 0	77 0 0 77 1 0 0	N N N N N N N	2 N N - 2 N N N	7 1 	15 3 1 3 2 2 0 2	124 61 16 34 13 24 6	109 28 10 32 14 15 1	90 15 13 21 17 6 1
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	2,240 65 107 1,005 13 401 — 41 598	3,958 64 113 1,254 549 461 257 503 490 62	6,239 140 181 1,556 1,502 695 2,595 3,030 1,062 95	41,083 903 1,298 16,390 91 5,241 4,946 4,575 6,885 754	48,097 924 1,389 10,814 10,250 4,044 7,656 6,221 6,024 775	 	0 0 0 0 0 0 0	1 0 0 0 0 1 0 0 0	2 — N N 2 N N N N	2 	16 — 11 4 — 1 —	20 0 0 8 5 0 1 1 1	69 4 1 35 17 3 18 15 5	159 4 2 76 54 2 9 5 4 3	165 2 3 86 35 5 8 11 14
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	547 62 1 — 484	1,478 484 199 268 502	2,286 605 357 1,048 719	17,767 5,099 2,558 3,585 6,525	21,437 6,401 1,473 6,031 7,532	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	_ _ _ _	4 1 1 0 1	65 14 40 11 18	23 12 4 2 5	37 17 9 8 3
W.S. Central Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	2,064 455 151 259 1,199	2,598 207 349 240 1,739	3,791 395 851 425 3,405	34,853 3,655 2,837 3,004 25,357	28,620 2,197 4,595 3,585 18,243	N N N N	0 0 0 0	1 0 1 0 0	1 N 1 N N	 N  N	1 - 1 -	6 0 1 1 3	28 8 4 11 16	38 2 3 11 22	43 3 13 10 17
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	512 46 49 182 33 202 —	1,407 449 310 57 47 181 164 121 20	1,834 672 488 233 363 291 394 216 35	8,065 716 1,141 1,007 690 1,706 1,490 1,304	17,907 5,535 4,579 985 721 2,321 2,226 1,209 331	39 39 N N N	95 91 0 0 0 1 0	171 169 0 0 0 6 2 7	1,279 1,261 N N N 11 5 2	1,267 1,234 N N N 10 8 15	12 10  2  	9 1 2 1 1 0 2 1	571 6 26 72 7 6 9 488 8	58 11 13 14 8 1 5 2	43 6 16 1 3 — 12 1 4
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	628 84 300 — 244	3,310 92 2,713 109 184 134	4,055 137 3,464 134 403 621	34,595 956 29,731 1,172 2,628 108	44,260 1,199 34,753 1,429 2,440 4,439	13 N 13 N N	39 0 39 0 0	217 0 217 0 0 0	505 N 505 N N	642 N 642 N N N	1 1 — — —	1 0 0 0 1	20 2 0 4 16 0	10 1 — 9 —	15 — — — 15
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	  82 	0  10 112 3	32 — 34 612 9	37 — 25 1,320 —	21 — 194 2,248 56	N _ N	0 0 0 0	0 0 0 0	N — N —	N — N —	N _ N	0 0 0 0	0 0 0 0	N - N	N - N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting years 2007 and 2008 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. Chlamydia refers to genital infections caused by *Chlamydia trachomatis*.

Scontains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

					onorrhea	1		Нае		us influen es, all sere	z <i>ae</i> , invas otypes†	ive			
	Current		ious eeks	Cum	Cum	Current		evious weeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	157	299	1,088	2,852	3,575	3,301	6,642	7,949	64,532	85,551	37	43	132	660	685
New England Connecticut	6 2	23 6	54 18	154 61	261 69	83 29	103 42	227 199	1,152 391	1,318 434	_	3	8 7	15 2	50 15
Maine§	1	3	10	26	39	2	2	8	23	19	_	0	3	4	3
Massachusetts New Hampshire	1	8 1	29 4	— 18	120 3	44 2	51 2	127 6	622 27	679 38	_	0	6 2	4	27 5
Rhode Island <sup>§</sup> Vermont <sup>§</sup>	1 1	1	15 8	20	30	6	7 1	14	89	133	_	0	2 1	2	_
Mid. Atlantic	33	3 58	118	29 485	648	799	659	5 1,004	6,723	15 8,831	<u> </u>	9	1 27	3 127	151
New Jersey	_	7	15	21	84	_	114	143	1,085	1,583	_	1	6	16	26
New York (Upstate) New York City	19 4	23 16	100 29	208 100	194 220	163 503	125 149	518 476	1,418 1,649	1,394 2,736	2	2 1	20 6	34 20	31 38
Pennsylvania	10	14	30	156	150	133	231	551	2,571	3,118	2	3	12	57	56
E.N. Central	17	47 14	91 33	426 85	579 160	244	1,299 378	2,578 772	12,187 2,473	18,417 4,450	4	6 2	23 7	93 26	89 29
Indiana	N	0	0	N	N	104	159	308	2,041	2,158	_	1	19	13	8
Michigan Ohio	1 16	11 15	22 37	88 195	165 173	101 39	275 361	540 1,558	3,678 2.710	4,474 5,537	4	0 2	3 6	5 47	10 36
Wisconsin	_	7	21	58	81	_	125	214	1,285	1,798	_	0	1	2	6
W.N. Central lowa	9	22 5	581 23	334 58	231 51	74 9	370 29	446 56	3,353 322	4,992 531	3	3	24 1	52 1	34
Kansas	1	3	11	22	29	49	39	102	374	601	_	0	1	1	4
Minnesota Missouri	3	0 8	575 23	115 90	4 108	9	65 187	90 255	713 1,549	857 2,617	1	0 1	21 5	10 29	10 15
Nebraska§	5	3	8	31	26	_	26	57	308	294	_	0	3	8	4
North Dakota South Dakota	_	0 1	3 6	7 11	1 12	7	2 5	6 11	26 61	23 69		0 0	1 0	3	1
S. Atlantic	43	54	96	578	618	1,025	1,577	2,337	14,800	19,072	19	11	30	192	172
Delaware District of Columbia	1	1 0	6 6	10 11	8 15	21 28	24 46	44 71	316 451	361 573	_ 1	0	1 1	1 1	4 2
Florida	30	23	47	254	265	349	485	619	5,786	4,686	3	3	10	56	49
Georgia Maryland <sup>§</sup>	8 1	12 5	40 18	173 46	141 62	3 86	215 130	621 235	37 1,488	4,147 1,358	3 2	2 2	8 6	50 41	39 30
North Carolina South Carolina§	N 2	0 3	0 6	N 26	N 17	<u> </u>	170 201	1,176 1,361	2,446 1,894	3,811 2,463	9	0 1	9 4	22 12	13 15
Virginia <sup>§</sup>	1	10	40	47	103	481	124	486	2,196	1,461	_	1	23	5	15
West Virginia E.S. Central	3	0 10	8 23	11 86	7 119	5 179	17 570	38 868	186 6,436	212 7,846	_ 1	0 2	3 8	4 33	5 37
Alabama§	3	4	11	53	70	23	206	282	2,090	2,734		0	3	5	10
Kentucky Mississippi	N N	0	0	N N	N N	_	80 112	161 401	973 1.429	479 2,108	_	0	1 2		2
Tennessee§		5	16	33	49	156	174	261	1,944	2,525	1	2	6	25	23
W.S. Central	4 4	6	21 9	43	78	604	1,006	1,347	11,940	12,116	_	2	15 2	29	25 1
Arkansas <sup>§</sup> Louisiana	_	1 1	14	19 8	31 27	88 75	80 194	138 384	1,202 1,569	1,016 2,755	_	0	2	2	4
Oklahoma Texas <sup>§</sup>	_ N	3 0	9	16 N	20 N	84 357	87 641	172 962	1,169 8,000	1,536 6,809	_	1 0	8 3	26 1	19 1
Mountain	13	31	68	209	327	119	259	335	1,394	3,259	4	5	14	95	87
Arizona	1	3	11 26	31	49 112	13	99 60	127 91	198	1,139	2	2	11	56 6	40 20
Colorado Idaho <sup>§</sup>	6 2	10 3	19	51 30	25	48 8	5	19	270 48	867 60		0	4 1	1	3
Montana <sup>§</sup> Nevada <sup>§</sup>	4	2	8 8	19 23	16 25	 50	1 44	48 85	19 450	29 560	_ 1	0	1 1	1 5	4
New Mexico <sup>§</sup>		2	5	14	34	_	30	64	281	403	_	1	4	9	12
Utah Wyoming <sup>§</sup>	_	7 1	33 3	32 9	56 10	_	14 1	39 5	128	183 18	_	1 0	6 1	17 —	7 1
Pacific	29	62	228	537	714	174	664	800	6,547	9,700	1	3	7	24	40
Alaska California	2 12	1 43	5 84	20 381	14 527	7 125	10 584	24 693	92 5,952	129 8,221	_	0	4 5	4 1	4 10
Hawaii	1	1	4	3	18	1	12	23	123	163	_	0	2	3	3
Oregon <sup>§</sup> Washington	6 8	9 8	19 137	95 38	101 54	41 —	24 19	63 142	363 17	279 908	<u>1</u>	1 0	5 3	16 —	23 —
American Samoa	_	0	0	_	_	_	0	1	1	2	_	0	0	_	_
C.N.M.I. Guam	_			_	_	_	_	13	 15	 18	_	0	1	_	_
Puerto Rico	_	5	31	5	67	5	4	23	63	98		0	1	_	
U.S. Virgin Islands		0	0				1	2		17	N	0	0	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Me \* Incidence data for reporting years 2007 and 2008 are provisional.
Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

(13th Week)*			Hepat	titis (viral,		- Lorianalloria									
		Previ	A				Prov	B					egionellos vious	sis	
	Current	52 we	eks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	52 w	veeks	Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	20	53	145	544	641	24	80	230	683	1,033	17	48	92	425	380
New England Connecticut	_	2 0	6 3	17 5	16 4	_	1 0	6 2	8 3	18 8	_	2 0	14 4	16 3	13 2
Maine§ Massachusetts	_	0	1 4	2	<u> </u>	_	0	2 1	3	1	_	0	2	_	 10
New Hampshire	_	0	3	1	3	_	0	1	1	4	_	0	2	3	_
Rhode Island <sup>§</sup> Vermont <sup>§</sup>	_	0 0	2 1	9	_	_	0	3 1	1	3 1	_	0	6 2	8 2	_ 1
Mid. Atlantic	2	9	21	75	95	1	8	17	61	142	1	14	37	85	101
New Jersey New York (Upstate)	_ 2	2 1	6 6	13 17	30 17	_	1 2	4 7	 11	42 13	_ 1	1 4	11 15	6 21	18 25
New York City	_	3	9	19	34	_	2	7	5	37	_	2	11	6	20
Pennsylvania E.N. Central	_ 1	2 5	6 13	26 62	14 85	1	3 8	14 15	45 80	50 127	_	5 11	21 30	52 105	38 95
Illinois	_	1	5	12	35	_	1	6	7	37	_	2	12	12	21
Indiana Michigan	1	0 2	4 6	4 36	4 21	_ 1	1 2	8 6	5 29	5 39	_	1 3	7 11	4 30	5 28
Ohio	_	1	3	8	19	3	2	7	36	35	_	4	17	59	35
Wisconsin W.N. Central	_ 4	0 3	1 24	2 69	6 14	_	0	1 8	3 17	11 46	_ 2	0 2	1 9	20	6 12
Iowa	_	1	5	21	5	_	0	2	2	9	_	0	2	4	1
Kansas Minnesota	_ 2	0 0	3 23	4 9	_ 1	_	0	2 5	4	4 2	_ 1	0	1 6		_
Missouri	_	0	3	13	3	_	1	5	9	24	_	1	3	7	6
Nebraska§ North Dakota	2	0 0	4 0	21 —	3	_	0 0	1 1	_	4	1	0 0	2	6	_2
South Dakota	_	0	1	1	2	_	0	1	_	3	_	0	1	1	1
S. Atlantic Delaware	6	10 0	21 1	80 1	112	9	18 0	54 2	202	259 3	7	8 0	27 2	92 1	91 1
District of Columbia	_	0	5	_	8	_	0	1	_	1	_	0	2	5	_
Florida Georgia	4 1	2 1	8 4	35 13	41 18	7 1	6 2	12 6	87 27	82 38	4	3 1	12 3	42 14	37 9
Maryland <sup>§</sup> North Carolina	1	1 0	5 9	11 9	15 6	_	2	7 16	20 24	26 48	3	1 0	5 4	16 3	22 9
South Carolina§	_	0	4	2	4	_	1	6	17	19	_	0	2	2	4
Virginia <sup>§</sup> West Virginia	_	1 0	5 2	8 1	20	1	2	15 23	21 6	35 7	_	1 0	6 5	6 3	6 3
E.S. Central	1	2	5	8	25	2	7	15	75	81	1	2	6	21	20
Alabama <sup>§</sup> Kentucky	_	0 0	4 2	1 3	5 5	_	2 2	6 7	23 23	29 7	_	0 1	1 3	2 11	2 9
Mississippi	_	0	1	_	4	1	0	3	9	10	_	0	0	_	_
Tennessee§ W.S. Central	1	1 5	3	4	11	1	2 19	8	20	35	1	1	4	8	9
Arkansas§	_	0	46 1	43 —	52 4	<u> </u>	19	112 4	148 2	164 16		0	12 3	12 1	1
Louisiana Oklahoma	_	0 0	3 8	1 3	7	_	1 1	6 38	12 15	22 8	_	0	2 2	_	1
Texas§	_	4	45	39	41	6	13	94	119	118	1	2	12	11	7
Mountain Arizona	1	4	10	50 30	64	1	3	8	21	61 31	2	2	6	26 15	20
Arizona Colorado	_	0	10 2	30 3	49 6	1	1 0	3	3 5	31 8	<u>2</u>	0	5 2	15 1	6 4
Idaho <sup>§</sup> Montana <sup>§</sup>	1	0 0	2 2	8	1	_	0	1 1	1	3	_	0	1 1	1 2	_1
Nevada <sup>§</sup>	_	0	1	_	4	_	1	3	8	12	_	0	2	2	2
New Mexico§ Utah	_	0 0	2 2	5 2	1 2	_	0 0	2 2	2 2	4 3	_	0 0	1 3	1 4	2
Wyoming§	_	0	1	2	1	_	0	1	_	_	_	0	1	_	2
Pacific Alaska	5 —	12 0	44 1	140 1	178 1	1	9	30 2	71 2	135 2	3	3 0	16 0	48	19
California	3	9	34	111	166	_	6	19	52	106	3	2	13	40	16
Hawaii Oregon§	_	0 1	2	2 10	2 4	_	0 1	2 3	1 7	18	_	0 0	1 2	1 4	_
Washington	2	1	8	16	5	1	1	10	9	9	_	0	2	3	3
American Samoa C.N.M.I.	_	0	0	_	_	_	0	13	_	_	N —	0	0	N —	_ N
Guam Puerto Rico	_	0	0	_	<u> </u>	_	0	1	_	1	_	0	0	_	_
U.S. Virgin Islands	_	1 0	4 0	2	26	_	1 0	5 0	4	19 —	_	0	0 0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting years 2007 and 2008 are provisional.

\* Data for acute hepatitis C, viral are available in Table I.

\* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

			yme disea	ase					Meningococcal disease, invasive <sup>†</sup> All serogroups						
	Commont	Prev		C	C	Cumant		ious eeks	C	C	Commont		vious	C	C
Reporting area	Current week	Med Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	veeks Max	Cum 2008	Cum 2007
United States	29	325	1,317	1,219	1,870	4	25	109	153	225	18	19	52	291	319
New England	_	44	302	57	150	_	1	23	1	9	_	0	3	2	12
Connecticut Maine§	_	12 6	214 61	33	29 12	_	0	16 2	_	_	_	0	1 1	1 1	2
Massachusetts	_	0	31	_	57	_	0	3	_	6	_	0	2	_	5
New Hampshire Rhode Island§	_	8 0	88 79	20 —	47	_	0	4 7	1	<u>1</u>	_	0	1 1	_	1
Vermont <sup>§</sup>	_	1	13	4	5	_	0	2	_	_	_	0	1	_	2
<b>Mid. Atlantic</b> New Jersey	22	169 40	678 189	717 96	975 309	1	7 1	18 4	33	56 9	3	2	8 1	34 1	36 6
New York (Upstate)	9	54	224	85	139	1	1	8	4	8	3	1	3	15	8
New York City Pennsylvania	 13	5 51	27 324	4 532	42 485	_	4 1	9 4	22 7	33 6	_	0 1	4 5	3 15	5 17
E.N. Central	_	11	169	18	64	_	2	7	30	37	1	3	8	48	54
Illinois	_	1	16	1	5	_	1	6	14	18	_	1	3	13	21
Indiana Michigan	_	0	7 5	1 5	1 3	_	0	2	1 5	1 7	_	0	4 2	8 10	6 9
Ohio	_	0	4	3	2	_	0	3	9	5	1	1	3	13	12
Wisconsin	_	10 4	149	8 4	53	_	0	1	1	6	_	0 1	1	4	6
W.N. Central lowa	_	1	714 11	4	22 6	<u>1</u>	0 0	8 1	6	12 2	2	0	8 3	35 8	26 7
Kansas Minnesota	_	0	2 714	_	1 15	_	0	1 8	_ 1	<del>_</del> 7	_	0	1 7	 15	2
Missouri	_	0	4	_	—	_	0	1	1	1	_	0	3	7	8
Nebraska <sup>§</sup> North Dakota	_	0	1 2	_	_	1	0	2 1	4	2	_	0	2 1	4	1
South Dakota	_	0	0	_	_	_	0	1	_	_	_	0	i	1	1
S. Atlantic	5	64	215	370	620	_	5	14	44	45	1	3	11	35	42
Delaware District of Columbia	1 2	12 0	34 7	96 20	105 2	_	0	1 1	_	1 1	_	0	1 0	_	_
Florida	_	1	11	9	4	_	1	7	15	10	1	1	7	16	11
Georgia Maryland§	_ 1	0 34	3 133	1 214	<u> </u>	_	1 1	3 5	12 14	5 14	_	0	3 2	3 4	6 11
North Carolina	_	0	8	2	5	_	0	4	2	4	_	0	4	3	4
South Carolina§ Virginia§	_ 1	0 17	4 62	1 26	4 76	_	0	1 7	1 —	10	_	0 0	3 2	9	4
West Virginia	_	0	9	1	_	_	0	1	_	_	_	0	1	_	_
<b>E.S. Central</b> Alabama <sup>§</sup>	1	0	5 3	1	5 1	_	0	3 1	2 1	7 1	_	1 0	3 2	18	15 3
Kentucky	_	0	2	=		_	0	1	1	1	_	0	2	4	2
Mississippi Tennessee <sup>§</sup>	_ 1	0	1 4	_ 1	<u> </u>	_	0	1 2	_	1 4	_	0	2	5 9	4
W.S. Central	1	1	8	4	12	2	1	55	8	16		2	11	27	36
Arkansas§	_	0	1	_	_	_	0	1	_	_	_	0	2	2	5
Louisiana Oklahoma	_	0	0	_	2	_	0	2 2	_ 1	8 1	_	0	3 4	6 6	11 6
Texas <sup>§</sup>	1	1	8	4	10	2	1	54	7	7	_	1	6	13	14
Mountain	_	1	3	3	2	_	1	5	6	16	1	1	4	20	26
Arizona Colorado	_	0 0	1	1 2	_	_	0 0	1 2	1 2	4 9	1	0	2 2	3 4	5 8
daho§	_	0	2	_	_	_	0	2	_	_	_	0	2	2	2
Montana <sup>§</sup> Nevada <sup>§</sup>	_	0	2	_	1 1	_	0 0	1 3	3	1	_	0	1 2	2 4	1
New Mexico§ Utah	_	0	2	_	_	_	0	1 3	_	1 1	_	0	1 2	3 1	1
Wyoming <sup>§</sup>	_	0	1	_	_	_	0	0	_		_	0	1	1	6
Pacific	_	3	11	45	20	_	3	9	23	27	10	4	20	72	72
Alaska California	_	0 2	2 9	— 44	2 18	_	0 2	0 8	 17	2 19	 10	0 3	1 12	— 55	1 55
Hawaii	N	0	0	N	N	_	0	1	1	1	_	0	2	_	2
Oregon <sup>§</sup> Washington	_	0	1 7	1	_	_	0	2 3	3 2	4 1	_	1 0	3 8	9 8	8 6
American Samoa	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
C.N.M.I. Guam	_	0	0	_	_	_	0	<u> </u>	_	_	_	<del>_</del> 0		_	_
Puerto Rico	N	0	0	N	N	_	0	1	_	_ 1	_	0	1	_	3
J.S. Virgin Islands	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting years 2007 and 2008 are provisional.

\* Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.

\* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

(13th Week)*	Pertussis Previous						Rab	ies, anim	al		Rocky Mountain spotted fever				
	0			0	0	0		/ious	0	0	0		vious	0	
Reporting area	Current week	Med	<u>eeks</u> Max	Cum 2008	Cum 2007	Current week	Med	reeks Max	Cum 2008	Cum 2007	Current week	Med	veeks Max	Cum 2008	Cum 2007
United States	40	167	637	1,181	2,349	41	98	176	660	1,067	2	34	147	52	119
New England	_	20	45	32	384	12	9	22	62	106	_	0	1	_	1
Connecticut Maine†	_	0 1	5 5	 14	19 28	3 4	4 1	10 5	37 7	46 21	N	0 0	0 0	N	N
Massachusetts New Hampshire	_	14 1	33 5	<u> </u>	304 16	N 1	0 1	0 4	N 7	N 9	_	0	1 1	_	1
Rhode Island† Vermont†	_	0 0	8 6	8 4	2 15	N 4	0 2	0 13	, N 11	N 30	_	0	0	_	_
Mid. Atlantic	8	22	38	4 172	396	8	25	56	79	281	_	1	7	3	10
New Jersey	_	3	7	2	61	_	0	0	_	_	_	0	3	_	1
New York (Upstate) New York City	6	8 2	24 7	59 15	197 44	<u>8</u>	9 0	20 5	74 5	80 17	_	0 0	1 3	1	4
Pennsylvania	2	7	22	96	94	_	13	44	_	184	_	0	3	2	5
E.N. Central Illinois	<u>4</u>	23 2	185 8	402 11	465 59	N	2	39 0	1 N	5 N	_	1 1	4 3	1	3 1
Indiana Michigan		0 3	12 16	4 35	3 97	_	0 1	1 28	_	4	_	0	2 1	_	_ 1
Ohio	1	12	176	352	213	_	1	11	1	1	_	0	2	1	1
Wisconsin W.N. Central	1	0 12	24 134	— 101	93 147	N 1	0 4	0 13	N 15	N 36	_	0 5	0 37	— 10	— 13
Iowa		2	8	19	47	1	0	3	2	4	_	0	4	_	1
Kansas Minnesota	_	2	5 131		48 8	_	1 0	7 6	9	21 3	_	0 0	2 4	_	3
Missouri Nebraska <sup>†</sup>	1	2 1	16 12	66 12	17 6	_	0	3 0	_	2	_	5 0	29 2	10	9
North Dakota	_	0	4	_	1	_	0	5	2	5	_	0	0	_	_
South Dakota S. Atlantic	10	0 15	7 48	2 126	20 254	— 15	0 40	2 63	2 428	1 548	_	0 14	1 111	 28	— 64
Delaware	_	0	2	1	1	_	0	0	_	_	_	0	2	1	4
District of Columbia Florida		0 3	1 9	2 31	2 81	_	0	0 9	 28	 124	_	0 0	1 3	1	3
Georgia Maryland <sup>†</sup>	_	0 2	3 6	2 17	13 43	1	5 9	31 18	87 86	51 86	_	0 1	6 6	3 7	4 10
North Carolina	4	3	34	39	59	13	9	19	100	102	_	5	96	11	32
South Carolina <sup>†</sup> Virginia <sup>†</sup>	4	2 2	22 11	17 17	21 31	_	0 12	11 31	102	31 132	_	0 2	7 11	4	4 7
West Virginia	_	0	12	_	3	1	0	11	25	22	_	0	3	1	_
E.S. Central Alabama <sup>†</sup>	_	6 1	35 6	49 15	71 22	1 —	3 0	7 0	29 —	30	1 —	5 1	16 10	4 2	24 9
Kentucky Mississippi	_	0 3	4 32	6 20	3 14	1	0	3 1	4	6	_	0	2	_	_ 1
Tennessee <sup>†</sup>	_	1	5	8	32	_	3	6	25	24	1	2	10	2	14
W.S. Central Arkansas†	_	20 1	112 17	44 8	110 11	2	1 1	23 3	13 12	16 7	_	1 0	30 15	4	2
Louisiana	_	0	2	_	6	_	0	0	_	_	=	0	2	2	1
Oklahoma Texas <sup>†</sup>	_	0 16	26 102	1 35	93	_	0	22 0	1	9	_	0 1	20 7		1
Mountain	11	19	40	138	327	_	2	8	10	1	_	0	4	1	1
Arizona Colorado	 5	2 5	10 14	15 27	96 85	N —	0	0	N	N —	_	0 0	1 2	_	_
Idaho <sup>†</sup> Montana <sup>†</sup>	<u> </u>	1	4 11	6 45	10 11	_	0	4	_	_	_	0	1 1	_	1
Nevada <sup>†</sup>	_	0	6	2	7	_	0	2	_	_	_	0	0	_	_
New Mexico <sup>†</sup> Utah	_	1 5	7 27	2 41	13 93	_	0	2 2	8	1	_	0 0	1 0	1	_
Wyoming <sup>†</sup>	_	0	2	_	12	_	0	4	2	_	_	0	2	_	_
Pacific Alaska	6 1	17 1	243 6	117 18	195 9	2	4 0	10 3	23 9	44 21	1 N	0	2	1 N	1 N
California Hawaii	_	8	32 2	23	136 8	2	3	8	14	23	1 N	0	2	1 N	1 N
Oregon <sup>†</sup>	4	2	14	25	15	_	0	3	_	_	_	0	Ĭ.	_	_
Washington	1	3	209	49	27		0	0	 N		N	0	0	N	N
American Samoa C.N.M.I.	_	0	0	_	_	N	0	0	N	_ 	N —	0	0	N —	N —
Guam Puerto Rico	_	0	0 1	_	_	_	0	0 5	_ 8	 15	N N	0	0	N N	N N
U.S. Virgin Islands	_	Ö	Ö	_	_	N	Ö	Ö	Ň	Ň	N	ő	Ö	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

† Incidence data for reporting years 2007 and 2008 are provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

(13th Week)*		S	almonello	sis		Shiga	. coli(STE	(C)†	Shigellosis						
		Prev	rious				Prev	/ious				Pre	vious		
Reporting area	Current week	52 w Med	eeks Max	Cum 2008	Cum 2007	Current week	Med 52 w	eeks_ Max	Cum 2008	Cum 2007	Current week	Med 52 v	veeks Max	Cum 2008	Cum 2007
United States	329	864	1,894	5,602	7,698	222	72	217	611	498	199	359	1,078	3,088	2,586
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	2 — — — 2 —	31 0 2 21 3 1	78 72 14 58 10 15	135 72 26 — 10 17	710 430 22 207 23 17 11	_ _ _ _ _	3 0 0 1 0 0	11 6 4 10 4 2 3	18 6 4 — 5 1 2	77 45 7 18 6 —	=	3 0 0 1 0 0	11 7 4 8 1 9	15 7 1 — 1 5	87 44 4 37 2 —
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	14 -9 - 5	108 19 26 25 34	190 48 63 52 69	612 16 174 185 237	1,063 217 246 258 342	193 — 192 — 1	9 1 3 1 2	27 7 12 5 11	225 — 206 4 15	64 21 18 5 20	15 — 14 1 —	19 4 4 7 2	154 11 19 18 141	255 35 77 116 27	131 22 21 72 16
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	25 — 5 20	104 30 11 19 25 14	255 188 34 43 64 50	569 142 44 129 200 54	1,021 383 94 153 202 189	2 - - 2 -	9 1 2 2 2 2	35 13 12 8 9 11	42 2 5 13 16 6	64 10 2 10 30 12	19 — — 19 —	57 15 5 1 18 4	134 27 82 7 104 13	546 172 173 11 163 27	245 131 13 12 55 34
W.N. Central lowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	24  5 3 12 4 	49 9 7 13 14 5 0 3	103 18 20 39 29 13 9	407 67 32 112 128 47 5	484 82 76 97 148 35 8 38	1 1 - - -	12 3 0 3 3 2 0	38 13 4 15 12 6 1	57 15 3 12 22 3 —	47 7 5 16 10 9	9 — 1 6 — 2	27 2 0 4 17 0 0	80 6 3 10 72 3 5 30	173 17 3 28 77 — 16 32	444 18 8 65 331 4 6
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	95 1 52 16 6 12 7 1	228 3 0 87 36 15 25 18 22 4	435 8 4 181 81 44 191 51 50 25	1,758 18 11 860 314 108 175 147 96 29	2,016 22 8 828 298 152 335 162 190 21	18 — 12 — 3 3 —	13 0 0 3 1 1 1 0 3 0	38 2 1 18 8 5 24 3 9	110 2 	108 4 — 28 16 16 16 2 25 1	47 — 13 12 1 4 17 —	82 0 0 34 29 2 1 6 3	153 2 4 75 86 7 12 20 14 62	786 — 8 245 350 14 25 125 19 —	850 3 3 543 236 20 14 12 19
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	22 7 6 2 7	59 16 10 13 17	144 50 23 57 34	368 125 64 62 117	489 138 92 101 158	2 1 — 1	4 1 1 0 2	26 19 12 1 12	44 25 4 1 14	23 5 7 1	17 6 1 1 9	49 13 8 18 7	177 43 35 111 32	386 106 41 111 128	219 88 22 52 57
W.S. Central Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	49 6 - 7 36	96 13 16 9 52	819 50 44 43 772	449 60 49 65 275	431 62 102 58 209	1 1 — —	5 0 0 0 3	13 3 0 3 11	32 5 — 2 25	31 6 3 4 18	65 5 — 1 59	48 2 9 3 33	653 11 22 9 631	578 46 33 24 475	198 16 72 11 99
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyomina <sup>§</sup>	62 8 47 1 5 —	50 17 10 3 1 5 5 4	83 39 45 10 10 12 13 17 5	477 173 136 28 12 42 46 27 13	495 175 120 25 21 53 49 37	5 3 1 1 — —	9 2 1 2 0 0 1 1	42 8 17 16 3 3 9	58 25 1 18 3 2 7 2	44 13 11 3 — 4 10 3	12 4 — — 8 —	17 10 2 0 0 1 1 0	40 30 6 2 2 10 6 5	132 74 5 2 — 39 8 1 3	168 81 24 3 5 11 26 5
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	36 1 21 — 1 13	114 1 85 5 6	391 5 230 14 16 152	827 9 649 42 58 69	989 22 773 57 63 74	_ _ _ _	9 0 5 0 1 1	38 1 33 4 11 17	25 — 14 2 3 6	40 — 24 3 5	15  13  2	27 0 22 0 1 2	70 1 61 3 6 21	217 — 189 7 10 11	244 5 204 11 9 15
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	=	0 0 14 0	1  5 55 0	1 2 35 —	_ 2 171 _	=	0 0 0 0	0 0 0 0	_ _ _ _	_ _ _ _	=	0 0 0 0	1 3 2 0	1 5 —	1 5 11 —

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Not Incidence data for reporting years 2007 and 2008 are provisional.
Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Med: Median.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

Reporting area   Repo	(13th Week)*	Stre	eptococca	l disease, i	invasive, gr	oup A	Streptococ	cus pneumoi	niae, invasiv Age <5 yea		ondrug resistant†	
United States		Current	Prev 52 w	ious eeks	Cum	Cum		nt <u>52</u> v	vious weeks	Cum		_
New England												
Conneclicut — 0 2 22 10 2 2 — 0 1 — 7 Massachelist — 1 0 3 9 7 — 0 1 1 — 7 Massachelist — 1 1 12 — 8 65 — 0 1 1 — 2 Vermorit — 0 3 3 9 7 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 2 Vermorit — 0 0 2 5 10 — 0 1 1 — 1  Mich. Atlantic 14 1 16 40 281 322 — 5 38 48 83 New Jersey — 2 11 12 65 — 1 6 9 16 New York (Lipstate) — 8 6 20 103 78 — 2 14 4 25 29 New York (Lipstate) — 8 6 20 103 78 — 2 14 4 25 29 New York (Lipstate) — 1 8 7 5 55 302 296 — 1 2 35 14 18 Vermority — 1 1 1 2 85 — 1 1 6 9 16 New York (Lipstate) — 1 1 5 24 18 New York (Lipstate) — 1 1 1 4 10 287 N N 0 0 0 N N N  E.N. Central — 2 1 1 1 3 4 32 — 5 20 8 8 7 N  Will michana — 2 1 1 1 3 4 32 — 1 5 20 8 8 7 N  Will michana — 2 1 1 1 3 4 32 — 1 5 20 8 8 7 N  Will michana — 2 1 1 1 3 4 32 — 1 5 20 8 8 7 N  Will michana — 2 1 1 1 3 4 32 — 1 5 20 8 8 7 N  Will michana — 2 1 1 1 3 4 32 — 1 5 2 2 8 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		109					27					
Maine												
New Hampshire						7					_	
Phode Islandri				12		65						
Vermonif — 0 2 5 10 — 0 1 — 1    Mid. Allantic									-			
New Jersey New York (Lipstelptelptelptelptelptelptelptelptelptelp												
New York (Lipstate)	Mid. Atlantic	14	16	40	261	322	_	5	38	48	63	
New York Cirity Pennenyahania 6 4 15 101 97 N 0 0 N N  E.N. Central Illinois — 4 11 67 106 — 1 6 18 12 Inclaina — 2 11 34 32 — 0 12 8 4 Inclaina — 7 4 14 90 79 — 1 5 20 85 73 Illinois — 1 6 18 12 Inclaina — 7 4 14 90 79 — 1 5 17 21 Illinois — 0 38 57 14 — 0 9 18 5  W.N. Central  39 5 33 127 107 2 3 3 22 36 30 Illinois  W.N. Central  39 5 33 127 107 2 3 3 22 36 30 Illinois — 0 0 0 — — — 0 0 0 — — — 0 0 — — — 1 Is 5 Illinois  W.N. Central  39 5 33 127 107 2 3 3 22 36 30 Illinois  W.N. Central  39 5 33 127 107 2 2 3 22 36 30 Illinois  W.N. Central  39 5 33 127 107 2 2 3 22 36 30 Illinois  W.N. Central  39 5 33 127 107 2 2 3 22 36 30 Illinois  W.N. Central  39 5 33 127 107 2 2 3 22 36 30 Illinois  W.N. Central  30 0 0 — — — 0 0 1 1 2 1 1 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1												
Pennsylvania												
Illinois												
Illinois	E.N. Central	8	15	55	302	296	_	5	20	85	73	
Michigan	Illinois	_	4	11	67	106		1	6	18	12	
Ohio         7         4         14         90         79         —         1         5         17         21           Wisconsins         —         0         38         57         14         —         0         9         18         5           Wisconsins         —         0         0         0         —         —         0         0         —         —         0         0         —         —         0         0         —         —         0         0         —         —         0         0         —         —         —         0         0         —         —         —         —         0         0         —         <												
Wisconsin         —         0         38         57         14         —         0         9         18         5           Win Central         39         5         33         127         107         2         3         22         36         30           lows         —         0         0         0         —         0         1         2         1           Kamasa         —         0         20         55         48         2         1         21         13         14           Missouri         —         2         10         33         30         —         0         2         15         12           Notrib Dakota         —         0         3         15         5         —         0         3         2         2           Notrib Dakota         —         0         2         9         3         3         4         7         5         10         63         98           Delaware         —         0         3         6         1         —         0         0         —         —         1         2         —           District Columbia												
Lowe							_					
Kansas — 0 2 8 14 — 0 1 2 1 Minmesota 35 0 20 55 48 2 1 21 13 14 Missouri — 2 110 33 30 — 0 2 15 12 North Dakota 3 0 3 15 5 — 0 3 2 2 2 North Dakota 3 0 3 7 7 7 — 0 0 0 — 1 1 South Dakota 3 0 3 7 7 7 — 0 0 1 4 — 1 South Dakota — 0 2 9 3 — 0 1 4 — — S.Atlantic 28 23 49 339 344 7 7 5 10 63 98 Delaware — 0 3 6 1 — 0 0 0 — — — District of Columbia — 0 4 11 4 — 0 0 1 2 — District of Columbia — 0 4 11 4 — 0 0 1 2 — District of Columbia — 0 4 11 4 — 0 0 1 2 — Florida 6 6 16 79 68 2 1 4 4 17 18 Georgia 5 4 13 71 78 — 0 0 4 4 — 29 Marylandi 4 4 4 9 6 67 65 3 1 1 5 2 3 2 4 North Carolinai 3 1 7 7 19 29 2 1 4 16 16 9 Virginia 1 3 12 33 53 — 0 3 3 3 17 Virginia 1 3 12 33 53 — 0 3 3 3 17 Virginia 1 3 12 33 53 — 0 3 3 3 17 Virginia 1 1 4 1 3 4 5 64 3 3 2 11 2 1 1 E.S. Central 1 4 1 4 13 4 5 64 3 3 2 11 2 2 1 1 E.S. Central 1 1 4 1 3 14 5 64 5 64 3 3 2 2 11 2 5 1 E.S. Central 1 2 7 68 132 94 11 0 18 N N N N N N N N N N N N N N N N N N	W.N. Central	39			127	107	2			36	30	
Minnesota		_		0			_	0		_	_	
Missouri         —         2         10         33         30         —         0         2         15         12           Nebraska¹         1         0         3         15         5         —         0         0         —         1           South Dakota         3         0         3         7         7         —         0         0         —         1           S. Atlantic         28         23         49         339         344         7         5         10         63         98           Delaware         —         0         4         11         4         —         0         0         —         —           Florida         8         6         16         79         68         2         1         4         17         18           Georgia         5         4         13         71         78         —         0         4         17         18           Georgia         5         4         13         71         78         —         0         4         17         18           Georgia         5         4         13         71         78												
North Dakota		_		10	33	30		0	2		12	
South Dakota												
S. Atlantic   28   23   49   339   344   7   5   10   63   98   Delaware   - 0   3   6   1   - 0   0   0												
Delaware		28					7					
Florida												
Georgia 5 4 13 71 78 — 0 4 — 29 Maryland <sup>6</sup> 4 4 4 9 9 67 65 3 1 1 5 23 24 North Carolina 7 2 2 22 42 40 N 0 0 0 N N N South Carolina 3 1 7 19 29 2 1 4 16 9 Virginia 1 3 12 33 53 — 0 3 3 17 Vest Virginia — 0 3 11 6 — 0 1 2 1  E.S. Central 1 4 13 45 64 3 2 11 27 27 Alabama <sup>6</sup> N 0 0 N N N N N 0 0 N N N Kentucky — 1 2 10 18 N 0 0 N N N Mississippi N 0 0 N N N N 1 0 0 N N N Mississippi N 1 3 13 35 46 2 2 2 9 21 25  W.S. Central 1 3 1 3 3 35 46 2 2 2 9 21 25  W.S. Central 1 9 4 11 4 61 68 76 Arkansas <sup>6</sup> — 0 1 1 9 — 0 2 3 5 Louisiana — 0 2 3 10 — 0 3 5 Louisiana — 0 2 1 1 1 9 — 0 2 2 3 5 Louisiana — 0 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1												
Maryland®         4         4         9         67         65         3         1         5         23         24           North Carolina         7         2         22         24         40         N         0         0         N         N           South Carolina®         3         1         7         19         29         2         1         4         16         9           Virginia*         1         3         12         33         53         —         0         3         3         17           E.S. Central         1         4         13         45         64         3         2         11         27         27           Alabama®         N         0         0         N         N         N         0         0         N         N           Kentucky         —         1         2         10         18         N         0         0         N         N           Mississippi         N         0         0         N         N         1         1         0         3         6         2           Tennessee®         1         3         13												
South Carolinas												
Virginia®         1         3         12         33         53         —         0         3         3         17           West Virginia         —         0         3         11         6         —         0         1         2         1           E.S. Central         1         4         13         45         64         3         2         11         27         27           Alabama®         N         0         0         N         N         N         0         0         N         N           Kentucky         —         1         2         10         18         N         0         0         N         N           Mississippi         N         0         0         N         N         1         0         3         6         2           Tennessee®         1         3         13         35         46         2         2         9         21         25           W.S. Central         12         7         68         132         94         11         4         61         68         76           Arkansas®         —         0         1         1												
West Virginia         —         0         3         11         6         —         0         1         2         1           E.S. Central         1         4         13         45         64         3         2         11         27         27           Alabama <sup>8</sup> N         0         0         N         N         N         0         0         N         N           Kentucky         —         1         2         10         18         N         0         0         N         N           Mississippi         N         0         0         N         N         1         0         3         6         2           Tennessee         1         3         13         35         46         2         2         9         21         25           W.S. Central         12         7         68         132         94         11         4         61         68         76           Arkansas <sup>8</sup> —         0         1         1         9         —         0         2         3         5           Louisiana         —         0         2         3												
Alabama <sup>§</sup> N         0         0         N         N         N         0         0         N												
Alabama <sup>§</sup> N         0         0         N         N         N         0         0         N	E.S. Central	1	4	13	45	64	3	2	11	27	27	
Mississippi         N         0         0         N         N         1         0         3         6         2           Tennessee§         1         3         13         35         46         2         2         9         21         25           W.S. Central         12         7         68         132         94         11         4         61         68         76           Arkansas§         —         0         1         1         9         —         0         2         3         5           Louisiana         —         0         2         3         10         —         0         3         —         20           Oklahoma         3         1         9         44         32         2         1         5         26         16           Texas§         9         5         59         84         43         9         3         56         39         35           Mountain         6         10         21         161         199         4         4         11         74         71           Arizona         4         4         9         69	Alabama§			0	N	N	N	0	0	N	N	
Tennessee®         1         3         13         35         46         2         2         9         21         25           W.S. Central         12         7         68         132         94         11         4         61         68         76           Arkansas®         —         0         1         1         9         —         0         2         3         5           Louisiana         —         0         2         3         10         —         0         2         3         5           Louisiana         —         0         2         3         10         —         0         3         —         20           Oklahoma         3         1         9         44         32         2         1         5         26         16           Texas®         9         5         59         84         43         9         3         56         39         35           Mountain         6         10         21         161         199         4         4         11         74         71           Arizona         4         4         9         69         <												
Arkansas⁵       —       0       1       1       9       —       0       2       3       5         Louisiana       —       0       2       3       10       —       0       3       —       20         Oklahoma       3       1       9       44       43       2       2       1       5       26       16         Texas⁵       9       5       59       84       43       9       3       56       39       35         Mountain       6       10       21       161       199       4       4       11       74       71         Arizona       4       4       9       69       67       1       2       8       50       37         Colorado       2       2       9       38       50       3       1       4       13       15         Idaho⁵       —       0       2       7       5       —       0       1       1       —         New Mexico⁵       —       0       1       2       2       N       0       0       N       N         Nev Mexico⁵       —       0												
Arkansas§       —       0       1       1       9       —       0       2       3       5         Louisiana       —       0       2       3       10       —       0       3       —       20         Oklahoma       3       1       9       44       42       2       1       5       26       16         Texas§       9       5       59       84       43       9       3       56       39       35         Mountain       6       10       21       161       199       4       4       11       74       71         Arizona       4       4       9       69       67       1       2       8       50       37         Colorado       2       2       9       38       50       3       1       4       13       15         Idaho§       —       0       2       7       5       —       0       1       1       —         New Mexico§       —       0       1       2       2       N       0       0       N       N         Nyoming§       —       0       1	W.S. Central	12	7	68	132	94	11	4	61	68	76	
Oklahoma         3         1         9         44         32         2         1         5         26         16           Texas§         9         5         59         84         43         9         3         56         39         35           Mountain         6         10         21         161         199         4         4         11         74         71           Arizona         4         4         9         69         67         1         2         8         50         37           Colorado         2         2         9         38         50         3         1         4         13         15           Idaho§         —         0         2         7         5         —         0         1         1         —           Montana§         N         0         0         N         N         —         0         1         —         —           New Mexico§         —         0         1         2         2         N         0         0         N         N           Utah         —         0         1         —         2         0	Arkansas§		0	1	1	9		0	2		5	
Texas§         9         5         59         84         43         9         3         56         39         35           Mountain         6         10         21         161         199         4         4         11         74         71           Arizona         4         4         9         69         67         1         2         8         50         37           Colorado         2         2         9         38         50         3         1         4         13         15           Idaho§         —         0         2         7         5         —         0         1         1         —           Montana§         N         0         0         N         N         N         —         0         1         —         —           Mew Mexico§         —         0         1         2         2         N         0         0         N         N           New Mexico§         —         0         1         5         12         37         —         0         2         1         3           Wyoming§         —         0         1		_										
Mountain         6         10         21         161         199         4         4         11         74         71           Arizona         4         4         9         69         67         1         2         8         50         37           Colorado         2         2         2         9         38         50         3         1         4         13         15           Idaho§         —         0         2         7         5         —         0         1         1 <t <td="">—           Montana§         N         0         0         N         N         —         0         1         1         —           Morada§         —         0         1         2         2         N         0         0         N         N           New Mexico§         —         2         5         33         36         —         0         3         9         16           Utah         —         1         5         12         37         —         0         2         1         3           Wyoming§         —         0         1         —</t>												
Arizona       4       4       9       69       67       1       2       8       50       37         Colorado       2       2       2       9       38       50       3       1       4       13       15         Idaho§       —       0       2       7       5       —       0       1       1       —         Montana§       N       0       0       N       N       —       0       1       1       —         Nevada§       —       0       1       2       2       N       0       0       N       N         New Mexico§       —       2       5       33       36       —       0       3       9       16         Utah       —       1       5       12       37       —       0       2       1       3         Wyoming§       —       0       1       —       2       —       0       0       —       —         Pacific       1       3       7       37       36       —       0       1       —       4         Alaska       —       0       0 <td< td=""><td>Mountain</td><td>6</td><td>10</td><td>21</td><td>161</td><td>199</td><td>4</td><td>4</td><td>11</td><td>74</td><td></td><td></td></td<>	Mountain	6	10	21	161	199	4	4	11	74		
Idaho§         —         0         2         7         5         —         0         1         1         —           Montana§         N         0         0         N         N         —         0         1         —         —           Nevada§         —         0         1         2         2         N         0         0         N         N           New Mexico§         —         2         5         33         36         —         0         3         9         16           Utah         —         1         5         12         37         —         0         2         1         3           Wyoming§         —         0         1         —         2         —         0         0         —         —           Pacific         1         3         7         37         36         —         0         1         —         4           Alaska         —         0         3         10         5         N         0         0         N         N           California         —         0         0         —         N         0	Arizona	4	4	9	69	67		2	8	50	37	
Montana <sup>§</sup> N         0         0         N         N         —         0         1         —         —           New Mexico <sup>§</sup> —         0         1         2         2         N         0         0         N         N           New Mexico <sup>§</sup> —         2         5         33         36         —         0         3         9         16           Utah         —         1         5         12         37         —         0         2         1         3           Wyoming <sup>§</sup> —         0         1         —         2         —         0         0         —         —           Pacific         1         3         7         37         36         —         0         1         —         4           Alaska         —         0         3         10         5         N         0         0         N         N           California         —         0         0         —         N         0         0         N         N           Hawaii         1         2         5         27         31         —												
Nevada <sup>§</sup> —       0       1       2       2       N       0       0       N       N         New Mexico <sup>§</sup> —       2       5       33       36       —       0       3       9       16         Utah       —       1       5       12       37       —       0       2       1       3         Wyoming <sup>§</sup> —       0       1       —       2       —       0       0       —       —         Pacific       1       3       7       37       36       —       0       1       —       4         Alaska       —       0       3       10       5       N       0       0       N       N         California       —       0       0       N       N       N       N       N         Hawaii       1       2       5       27       31       —       0       1       —       4												
Utah     —     1     5     12     37     —     0     2     1     3       Wyoming <sup>§</sup> —     0     1     —     2     —     0     0     —     —       Pacific     1     3     7     37     36     —     0     1     —     4       Alaska     —     0     3     10     5     N     0     0     N     N       California     —     0     0     —     N     0     0     N     N       Hawaii     1     2     5     27     31     —     0     1     —     4	Nevada <sup>§</sup>	_	0	1	2	2	N	0	0		N	
Wyoming§         —         0         1         —         2         —         0         0         —         —           Pacific         1         3         7         37         36         —         0         1         —         4           Alaska         —         0         3         10         5         N         0         0         N         N           California         —         0         0         N         N         0         0         N         N           Hawaii         1         2         5         27         31         —         0         1         —         4												
Pacific         1         3         7         37         36         —         0         1         —         4           Alaska         —         0         3         10         5         N         0         0         N         N           California         —         0         0         —         —         N         0         0         N         N           Hawaii         1         2         5         27         31         —         0         1         —         4												
Alaska     —     0     3     10     5     N     0     0     N     N       California     —     0     0     —     —     N     0     0     N     N       Hawaii     1     2     5     27     31     —     0     1     —     4		1	3	7	37		_	Ο	1	_	4	
Hawaii 1 2 5 27 31 — 0 1 — 4	Alaska		0	3		5	N	0	0	N	N	
Oregon§ N 0 0 N N N 0 0 N N	Oregon§			0			 N	0	0	 N		
Washington N 0 0 N N N 0 0 N N												
American Samoa — 0 4 — — N 0 0 N N	American Samoa	_	0	4	_	_	N	0	0	N	N	
C.N.M.I. — — — — — — — — — — — —			_	_			_	_	_	_	_	
Guam — 0 0 — — 0 0 — — Puerto Rico N 0 N N N N N N N N												
U.S. Virgin Islands — 0 0 — — N 0 0 N N												

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting years 2007 and 2008 are provisional.

† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).

\* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

		St	reptococ All ages		oniae, inva	sive disease					0.100					
			;	Age <5 years					Syphilis, primary and secondary							
	Current	Prev 52 we		Cum	Cum	Current		vious /eeks	Cum	Cum	Current		vious veeks	Cum	Cum	
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007	
United States	37	43	97	788	883	7	8	23	117	170	129	221	286	2,389	2,410	
New England	1	1	6	11	51	_	0	2	2	4	7	6	14	63	48	
Connecticut	_	0	4	_	32	_	0	1	_	3	_	0	6	3	6	
Maine§ Massachusetts	1	0 0	2	6	4	_	0	1 0	1	_	6	0 3	2 10	1 54	32	
New Hampshire	_	0	0	_	_	_	0	Ö	_	_	1	0	3	3	4	
Rhode Island§	_	0	2	2	7	_	0	1	_	1	_	0	5	2	5	
Vermont§	_	0	2	3	8	_	0	1	1	_	_	0	5	_	1	
Mid. Atlantic New Jersey	3	2 0	6 0	43	60	1	0	2	8	14	30	32 5	45 10	413 56	391 51	
New York (Upstate)	1	1	4	11	20	1	0	1	2	7	4	3	10	27	29	
New York City Pennsylvania		0 1	0 6	32	<u>—</u> 40	_	0	0 2	<u> </u>	7	23 3	18 5	30 12	266 64	249 62	
E.N. Central	9	13	46	224	241	1	2	14	31	38	11	15	27	181	216	
Illinois	_	2	13	43	51		0	6	9	16		6	14	25	101	
Indiana	_	3	28	46	36	_	0	11	5	3	4	1	6	34	14	
Michigan Ohio	9	0 6	1 17	3 132	154	_ 1	0 1	1 3	1 16	— 19	2 5	2 4	12 15	29 82	32 54	
Wisconsin	_	Ő	0	_	_	<u>.</u>	Ö	Ö	_	_	_	1	4	11	15	
W.N. Central	1	2	49	43	70	_	0	2	1	9	_	7	14	85	62	
Iowa Kansas	_	0	0	_		_	0	0 1	_		_	0	2	1 6	2 5	
Minnesota	_	0	7 46	4	42 —	_	0	1	_	5	_	1	5 4	24	13	
Missouri	1	1	8	39	25	_	0	1	1	_	_	5	10	52	42	
Nebraska§ North Dakota	_	0	1 0	_	1	_	0	0	_	_	_	0	1 1	2	_	
South Dakota	_	0	1	_	2	_	0	1	_	2	_	0	3	_	_	
S. Atlantic	17	18	44	346	375	5	4	11	54	87	29	50	152	479	481	
Delaware	_	0	1	_	2	_	0	1	_	1	_	0	3	1	2	
District of Columbia Florida	 12	0 11	3 27	10 198	4 200	<del></del> 5	0 2	0 7	34	<u>-</u>	2 9	2 17	12 35	22 196	49 135	
Georgia	5	5	17	120	154	_	1	5	16	34	1	7	131	12	56	
Maryland <sup>§</sup> North Carolina	N	0	2	3 N	N	N	0	1 0	1 N	N	8 1	6 5	15 23	83 78	72 91	
South Carolina		0	0	_	_	_	0	0	_	_		1	11	18	21	
Virginia <sup>§</sup>	N	0	0	N	N	N	0	0	N	Ñ	8	4	16	69	53	
West Virginia	_	1	12	15	15	_	0	1	3	5		0	1	_	2	
E.S. Central Alabama§	6 N	4 0	12 0	99 N	49 N	N	1	4 0	13 N	10 N	15 6	20 8	31 17	254 111	181 62	
Kentucky	2	0	3	18	11	_	Ö	2	4	1	_	1	4	14	22	
Mississippi	_	0	0	_	_	_	0	0	_	_	_	2	15	25	27	
Tennessee§	4	3	12	81	38	_	0	3	9	9	9	8	15	104	70	
W.S. Central Arkansas§	_	1 0	5 1	19 3	28 1	_	0	2 1	5 2	2	25 1	40 2	56 10	474 23	373 29	
Louisiana	_	1	4	16	27	_	0	2	3	2	5	11	22	82	80	
Oklahoma Texas <sup>§</sup>	N	0 0	0	_N	N	N	0	0	_N	N	1 18	1 26	5 46	17 352	20 244	
	_	1		3	9			2	2	6		9	28			
Mountain Arizona	_	0	5 0	_	<del>-</del>	_	0	0	_	_	1	5	20 20	50 2	104 47	
Colorado		0	0	_		_	0	0	_		1	1	7	20	12	
Idaho <sup>§</sup> Montana <sup>§</sup>	N	0	0	N	N	N	0	0	N	N	_	0	1 3	1	1 1	
Nevada <sup>§</sup>	N	0	0	N	N	N	0	0	N	N	_	2	6	19	26	
New Mexico§	_	0	1 5	_	7	_	0	0	_	 5	_	1 0	3	8	12	
Utah Wyoming <sup>§</sup>	_	0	2	3	2	_	0	2 1	2	5 1	_	0	2 1	_	4 1	
Pacific	_	0	0	_	_	_	0	1	1	_	11	42	61	390	554	
Alaska	N	0	0	N	N	N	0	0	N	N	_	0	1	_	2	
California Hawaii	_ N	0	0	N —	N	N	0	0 1	N 1	N	5	39 0	58 2	333 7	525 1	
Oregon§	N	0	0	N	N	N	0	0	N	N	_	0	2	5	4	
Washington	N	0	0	N	N	N	0	0	N	N	6	3	13	45	22	
American Samoa	N	0	0	N	N	N	0	1	N	N	_	0	4	_	_	
C.N.M.I. Guam	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_	
Puerto Rico	_	0	0	_	_	_	0	0	_	_	4	2	10	32	31	
U.S. Virgin Islands	_	0	0				0	0				0	0	_		

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not no U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: M

† Incidence data for reporting years 2007 and 2008 are provisional.

† Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 29, 2008, and March 31, 2007 (13th Week)\*

		Neuroinvasive				us disease† Nonneuroinvasive§									
		Prev				Previous				Previous					
Reporting area	Current week	52 we	eeks Max	Cum 2008	Cum 2007	Current week	Med 52 w	reeks Max	Cum 2008	Cum 2007	Current week	52 w	eeks Max	Cum 2008	Cum 2007
United States	414	585	1,350	6,984	12,222	week	1 Ivieu	141	2006	4	week	2	299	2006	2007
New England	6	12	47	143	180	_	0	2	_	_	_	0	2	_	_
Connecticut	_	0	1	_	1	_	Ő	2	_	_	_	Ö	1	_	_
Maine <sup>¶</sup>	_	0	0	_	_	_	0	0	_	_	_	0	0	_	-
Massachusetts New Hampshire	 5	0 6	0 18	<u> </u>	90	_	0	2	_	_	_	0	2	_	_
Rhode Island <sup>1</sup>	_	0	0	_	_	_	Ő	Ö	_	_	_	Ö	1	_	_
Vermont <sup>¶</sup>	1	6	38	76	89	_	0	0	_	_	_	0	0	_	-
Mid. Atlantic	58	63	154	616	1,736	_	0	3	_	_	_	0	3	_	-
New Jersey New York (Upstate)	N N	0	0	N N	N N	_	0	1 1	_	_	_	0	0 1	_	_
New York City	N	0	0	Ň	N	_	0	3	_	_	_	Ö	3	_	_
Pennsylvania	58	63	154	616	1,736	_	0	1	_	_	_	0	1	_	-
E.N. Central	56	158	358	1,621	3,764	_	0	18	_	_	_	0	12	_	
Illinois Indiana	7	3 0	11 222	76 —	56	_	0 0	13 4	_	_	_	0	8 2	_	_
Michigan	14	67	154	730	1,482	_	0	5	_	=	_	0	0	_	_
Ohio	35	65	208	815	1,806	_	0	4	_	_	_	0	3	_	
Wisconsin	_	8	80	_	420	_	0	2	_	_	_	0	2	_	_
W.N. Central	10 N	22 0	92 0	317 N	635 N	_	0	41 4	_	_	_	1 0	117	_	_
owa Kansas	N 1	5	28	N 122	N 287	_	0	3	_	_	_	0	3 7	_	=
Minnesota	_	0	0	_	_	_	0	9	_	_	_	0	12	_	_
Missouri	9	12	78	181	239	_	0	9	_	_	_	0	3	_	_
Nebraska <sup>¶</sup> North Dakota	N	0	0 1	N 1	N 84	_	0	5 11	_	_	_	0	15 49	_	_
South Dakota	_	1	14	13	25	_	Ö	9	_	_	_	Ö	32	_	_
S. Atlantic	64	90	182	1,103	1,715	_	0	12	_	_	_	0	6	_	_
Delaware	_	1	4	5	10	_	0	1	_	_	_	0	0	_	-
District of Columbia Florida	 37	0 26	8 87	5 584	366	_	0	0 1	_	_	_	0	0	_	_
Georgia	N	0	0	N	N	_	0	8	_	_	_	Ö	5	_	_
Maryland <sup>1</sup>	N	0	0	N	N	_	0	2	_	_	_	0	2	_	-
North Carolina South Carolina <sup>1</sup>	N 14	0 14	0 50	N 220	N 481	_	0	1 2	_	_	_	0	1	_	_
Virginia <sup>¶</sup>		19	80	67	436	_	Ő	1	_	_	_	Ö	i	_	_
West Virginia	13	18	66	222	422	_	0	0	_	_	_	0	0	_	_
E.S. Central	6	13	82	310	151	_	0	11	_	4	_	0	14	_	_
Alabama <sup>¶</sup> Kentucky	6 N	13 0	82 0	309 N	149 N	_	0 0	2 1	_	_	_	0	1 0	_	_
Mississippi	_	Ö	1	1	2	_	Ő	7	_	3	_	Ö	12	_	_
Tennessee <sup>¶</sup>	N	0	0	N	N	_	0	1	_	1	_	0	2	_	_
W.S. Central	185	172	839	2,471	3,057	_	0	34	_	_	_	0	18	_	-
Arkansas <sup>¶</sup> Louisiana	2	12 1	46 8	165 20	200 46	_	0	5 5	_	_	_	0	2 3	_	_
Oklahoma	N	0	0	N	N N	_	0	11	_	_	_	0	7	_	
Texas <sup>¶</sup>	183	159	822	2,286	2,811	_	0	18	_	_	_	0	10	_	_
Mountain	27	35	130	395	965	_	0	36	_	_	_	1	143	_	_
Arizona Colorado	10	0 13	0 62	— 158	357	_	0	8 17	_	_	_	0	10 65	_	_
Colorado  daho <sup>¶</sup>	N	0	0	158 N	357 N	_	0	3	_	_	_	0	65 22	_	
Montana <sup>¶</sup>	17	6	40	113	118	_	0	10	_	_	_	0	30	_	_
Nevada <sup>¶</sup> New Mexico <sup>¶</sup>	N	0 4	0 37	N 46	N 132	_	0	1 8	_	_	_	0	3 6	_	_
New Mexico	_	7	37 72	46 77	350	_	0	8	_	_	_	0	8	_	
Wyoming <sup>¶</sup>	_	Ó	9	1	8	_	Ö	4	_	_	_	ő	33	_	_
Pacific	2	0	4	8	19	_	0	18	_	_	_	0	23	_	_
Alaska California	2	0	4	8	19	_	0	0	_	_	_	0	0	_	_
California Hawaii	_	0	0	_	_	_	0	17 0	_	_	_	0	21 0	_	_
Oregon <sup>¶</sup>	N	0	0	N	N	_	0	3	_	_	_	Ö	4	_	_
Washington	N	0	0	N	N	_	0	0	_	_	_	0	0	_	-
American Samoa	N	0	0	N	N	_	0	0	_	_	_	0	0	_	-
C.N.M.I. Guam	_	3	 19	 15	— 84	_			_	_	_	0		_	=
Puerto Rico	_	11	37	55	205	_	0	0	_	_	_	0	0	_	
U.S. Virgin Islands	_	0	0	_		_	Ō	Ö	_	_	_	Ö	Ō	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting years 2007 and 2008 are provisional.
Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenzanassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths	in 122 U		s,* week			1 29, 2	2008 (13	Bth Week)	All ca	uses by	age (yea	are)			
	All	All C	auses, D	y age (ye	a13)		P&I <sup>†</sup>		All	uses, by	age (yea	113)			P&I <sup>†</sup>
Reporting Area	Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total
New England Boston, MA	635 129	464 81	122 30	27 9	7 2	14 6	79 18	S. Atlantic Atlanta, GA	1,086 103	708 61	259 28	68 10	35 3	15 1	67
Bridgeport, CT	35	22	12	1	_	_	4	Baltimore, MD	133	78	39	8	5	2	10
Cambridge, MA	12	10	2	_	_	_	2	Charlotte, NC	102	64	28	5	3	2	9
Fall River, MA Hartford, CT	31 63	27 37	3 19	1 1	_	<u> </u>	3 6	Jacksonville, FL Miami, FL	166 82	105 62	41 14	13 3	6 2	1	9 7
Lowell, MA	33	24	5	4	_		5	Norfolk, VA	57	33	19	_	3	2	3
Lynn, MA	12	8	2	2	_	_	1	Richmond, VA	61	44	13	2	1	1	2
New Bedford, MA New Haven, CT	35 43	27 37	7 3	1 3	_	_	1 12	Savannah, GA St. Petersburg, FL	65 66	42 47	16 7	5 5	2 4	3	8
Providence, RI	80	67	8	3	1	1	7	Tampa, FL	236	163	49	16	6	2	15
Somerville, MA	2	1	_	1	_	_	1	Washington, D.C.	U	U	U	U	U	U	U
Springfield, MA	49 34	36 27	11 5	1	_ 1	1 1	7 5	Wilmington, DE	15	9	5	1	_	_	1
Waterbury, CT Worcester, MA	77	60	15	_	1	1	7	E.S. Central	1,022	689	222	69	23	18	99
Mid. Atlantic	2,180	1,554	438	101	46	37	131	Birmingham, AL Chattanooga, TN	197 133	132 104	45 19	17 6	2	1	19 15
Albany, NY	54	41	7	3	2	1	4	Knoxville, TN	126	90	21	8	4	3	13
Allentown, PA	28	24	2	1	1	_	1	Lexington, KY	79	51	18	7	2	1	4
Buffalo, NY Camden, NJ	74 32	57 19	12 9	3 2	2 1	_ 1	8 1	Memphis, TN Mobile, AL	131 119	100 67	20 39	7 9	3 2	1 2	11 11
Elizabeth, NJ	25	16	6	2	1		1	Montgomery, AL	68	42	19	4	1	2	14
Erie, PA	52	40	11	1	_	_	5	Nashville, TN	169	103	41	11	6	8	12
Jersey City, NJ New York City, NY	26	13 801	10 219	1 52	 27	2 12	2 48	W.S. Central	1,676	1,076	412	118	36	33	138
Newark, NJ	1,114 46	24	13	4	1	4	2	Austin, TX	122	79	28	6	5	4	8
Paterson, NJ	27	22	4	_	1	_	3	Baton Rouge, LA Corpus Christi, TX	53 62	34 48	12 12	3 2	2	2	9
Philadelphia, PA	247	142	66	17	8	13	11	Dallas, TX	218	120	61	25	10	_	21
Pittsburgh, PA§ Reading, PA	50 34	39 28	9 4	1 1	1	1	5 3	El Paso, TX	141	104	21	10	2	4	7
Rochester, NY	139	112	21	6		_	17	Fort Worth, TX	147	103	36	3	2	3	15
Schenectady, NY	26	22	4	_	_	_	3	Houston, TX Little Rock, AR	285 85	158 53	81 19	34 9	6 3	5 1	23
Scranton, PA Syracuse, NY	33 115	30 83	3 26	3	_	_ 3	4 10	New Orleans, LA <sup>¶</sup>	Ü	Ü	Ü	Ü	U	U	U
Trenton, NJ	23	15	5	2	1	_	<del>-</del>	San Antonio, TX	295	202	77	10	2	4	28
Utica, NY	14	12	2	_	_	_	3	Shreveport, LA Tulsa, OK	108 160	73 102	18 47	9 7	2 2	6 2	11 16
Yonkers, NY	21	14	5	2	_	_	_	Mountain	1,316	891	276	83	32	30	114
E.N. Central Akron, OH	2,456 64	1,605 39	591 16	142 4	44 4	74 1	204 1	Albuquerque, NM	144	107	25	9	1	2	13
Canton, OH	61	40	17	1	_	3	7	Boise, ID	97	68	15	6	3	5	11
Chicago, IL	390	251	95	28	6	10	43	Colorado Springs, CO Denver, CO	76 114	45 68	16 30	10 10	3 1	2 4	4 13
Cincinnati, OH Cleveland, OH	122 316	74 222	25 79	8 4	2	13 8	18 17	Las Vegas, NV	291	195	69	19	5	3	23
Columbus, OH	214	131	59	14	3	7	22	Ogden, UT	30	22	4	1	3	_	2
Dayton, OH	148	105	29	6	3	5	14	Phoenix, AZ Pueblo, CO	203 31	132 25	43 3	10 2	6 1	9	16 3
Detroit, MI Evansville, IN	216 59	99 46	67 11	38 1	4 1	8	15 2	Salt Lake City, UT	138	86	33	8	7	4	14
Fort Wayne, IN	89	57	26	4		_	8	Tucson, AZ	192	143	38	8	2	1	15
Gary, IN	15	7	4	2	2	_	1	Pacific	1,799	1,278	354	99	43	24	186
Grand Rapids, MI	34	24	7 50	1 8	2	_	1	Berkeley, CA	19	10	8	1	_	_	1
Indianapolis, IN Lansing, MI	214 55	143 36	15	4	6	7	18 2	Fresno, CA Glendale, CA	143 20	99 17	29 3	10	4	1	13 3
Milwaukee, WI	116	75	33	4	1	3	6	Honolulu, HI	86	64	15	5	2	_	12
Peoria, IL	66	40	16	3	2	5	7	Long Beach, CA	87	55	16	11	3	2	9
Rockford, IL South Bend, IN	62 59	53 40	3 15	3 3	3	_ 1	8 5	Los Angeles, CA Pasadena, CA	276 20	193 15	48 4	14	17 1	4	42
Toledo, OH	101	71	21	6	2	i	4	Portland, OR	113	73	31	9		_	11
Youngstown, OH	55	52	3	_	_	_	5	Sacramento, CA	213	163	37	9	2	2	20
W.N. Central	640	451	122	34	16	16	70	San Diego, CA San Francisco, CA	174 126	122 81	37 31	8 11	5	1 3	16 16
Des Moines, IA	76 40	61	11	2	1	1	4	San Jose, CA	189	144	34	5	1	5	20
Duluth, MN Kansas City, KS	48 23	36 18	9 3	_	3 2	_	8 3	Santa Cruz, CA	32	26	4	2	_	_	2
Kansas City, MO	104	71	23	4	1	5	7	Seattle, WA	122	76	30	8	4	4	8
Lincoln, NE	33	23	10		_	_	4	Spokane, WA Tacoma, WA	66 113	53 87	9 18	1 5	1 3	2	8 5
Minneapolis, MN Omaha, NE	77 101	46 70	13 23	10 6	5 1	3 1	9 14	Total	12,810**		2,796	741	282	261	1,088
St. Louis, MO	34	16	23 9	5	1	2	3	Iotal	12,010	0,710	۷,730	/41	202	201	1,000
St. Paul, MN	64	53	7	_	1	3	12								
Wichita, KS	80	57	14	7	1	1	6								

U: Unavailable.

U: Unavailable. —:No reported cases.

\* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

<sup>§</sup> Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. 
¶ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.

\*\*Total includes unknown ages.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwrtoc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to www.mmwrq@cdc.gov.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in MMWR were current as of the date of publication.

☆U.S. Government Printing Office: 2008-723-026/41087 Region IV ISSN: 0149-2195